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General Introduction 9
BARRETT’S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA
Barrett’s esophagus is a premalignant condition that is most likely caused by gas-
troesophageal reflux. In the western world, about 30% of adults have reflux com-
plaints, such as heartburn, and about 10% of reflux patients will develop Barrett’s 
esophagus [1]. Barrett’s esophagus is characterized by chronic inflammation, and 
like other chronic inflammatory lesions, it is associated with cancer development. 
Patients with Barrett’s esophagus have a 30 times increased risk for the devel-
opment of esophageal adenocarcinoma compared to the general population [2]. 
Barrett’s esophagus can progress to esophageal adenocarcinoma through the in-
termediate stages low-grade dysplasia and high-grade dysplasia [3]. Esophageal 
adenocarcinoma has a poor prognosis, the overall survival is only 15-20% [2].
Endoscopical and histological diagnosis
During upper gastrointestinal (GI) endoscopy, Barrett’s esophagus is clearly visible 
as salmon-red appearing mucosa in the distal esophagus. Histologically, Barrett’s 
esophagus is defined as the presence of columnar epithelium of the intestinal type 
containing goblet cells, which is called intestinal metaplasia. In addition to intes-
tinal metaplasia, gastric mucosa of the cardiac or fundic type is also frequently 
present in the esophagus, but this type of mucosa is not premalignant and there-
fore not regarded as Barrett’s esophagus [2]. Patients with Barrett’s esophagus 
are invited to enter surveillance-programs to screen for dysplasia and adenocar-
cinoma development. They undergo upper GI endoscopy every two years, during 
which at every 2 cm of the columnar segment, 4-quadrant biopsies are taken  [4]. 
These biopsy sets are routinely evaluated by a pathologist for the presence of low-
grade dysplasia, high-grade dysplasia or esophageal adenocarcinoma. 
Maintenance and treatment
Once established, Barrett’s esophagus cannot regress to normal squamous epi-
thelium unless the epithelium is completely removed. Therefore, patients receive 
therapies with the intention of minimizing the risk of adenocarcinoma develop-
ment. In order to reduce acid reflux, patients receive proton-pump inhibitor ther-
apy [5]. In patients with severe reflux complaints, surgical nissen fundoplication 
can partly restore the function of the upper esophageal sphincter [6]. To eliminate 
high-grade dysplasia endoscopically, patients are often treated by photodynamic 
therapy and/or endoscopic mucosal resection [7]. Patients with esophageal ad-
enocarcinoma are only only considered for curative surgery when they have no or 
only loco-regional lymph node metastases [8]. Patients who are not considered 
for surgery, undergo palliative treatment, usually brachytherapy or stent-place-
ment [9]. 
Molecular biology of Barrett’s esophagus and esophageal adenocarcinoma
The differentiation of normal squamous epithelium into intestinal metaplasia, and 
the progression through the Barrett’s esophagus - dysplasia - adenocarcinoma 
sequence is mediated by molecular alterations that are probably induced by the 
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chronic inflammation present in Barrett’s esophagus [10]. The transformation 
from a normal cell into a tumor cell is thought to require four to seven alterations, 
each of them leading to the induction of proteins involved in tumorigenesis or 
downregulation of proteins protecting the cell [11]. These alterations are usually 
comprised of genetic lesions or altered methylation patterns of genes, resulting 
in changes in mRNA and protein expression. In the Erasmus MC a wide range of 
expertise on molecular biological research on Barrett’s esophagus and esophageal 
adenocarcinoma is present in several departments. The research described in this 
thesis connects to previously published Erasmus MC theses on molecular biology 
of esophageal adenocarcinoma [12, 13].
Aim of this thesis
The aim of this thesis is to characterize the expression of several genes involved 
in intestinal differentiation, chronic inflammation, and mucosal protection during 
intestinal differentiation in Barrett’s esophagus, and progression to dysplasia and 
esophageal adenocarcinoma.
Outline of the thesis
In chapter 2, an overview of the existing literature about molecular alterations in 
intestinal differentiation and carcinogenesis in the esophagus is given. In chapter 
3, the expression of the intestinal transcriptionfactor CDX2 in Barrett’s esopha-
gus is assessed. In chapter 4 and chapter 5, the question whether or not CDX2 
is present in gastric type mucosa of the esophagus is discussed. In chapter 6, 
the expression of seven principal mucins in Barrett’s esophagus, dysplasia and 
esophageal adenocarcinoma is investigated. In chapter 7, genes involved in high-
grade dysplasia development are identified with the use of transcription profiling 
analysis (microarray). In chapter 8, the influence of bile acids on chemokine ex-
pression is investigated in an esophageal cell-line model, and chemokine tran-
scription is also assessed in reflux esophagitis, Barrett’s esophagus, high-grade 
dysplasia, and esophageal adenocarcinoma. In the final chapter, chapter 9, the 
results described in this thesis are summarized and discussed. 
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SUMMARY
The incidence of esophageal adenocarcinoma has risen significantly over the last 
decades. During esophageal carcinogenesis many molecular alterations occur that 
disrupt essential cellular processes, directing the cell to a rapidly proliferating, 
immortal state. The chronic inflammation that is present in Barrett’s esophagus 
creates an environment in which such molecular alterations are both induced and 
tolerated. Here, the novel insights in the molecular mechanisms that underlie the 
development of esophageal adenocarcinoma are reviewed, focussing on the role 
of inflammation, angiogenesis, apoptosis inhibition, loss of cell cycle control and 
loss of cell-cell adhesion. These novel developments will open new perspectives 
for diagnosis, treatment, and prevention of esophageal adenocarcinoma.
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INTRODUCTION
Esophageal adenocarcinoma is generally believed to develop from Barrett’s es-
ophagus in a step-wise progression involving low-grade dysplasia and subse-
quently, high-grade dysplasia. This is based on the observation that the different 
stages are often observed adjacent to each other in esophageal biopsies. In addi-
tion, many patients with low-grade and high-grade dysplasia progress to adeno-
carcinoma [1, 2]. The progression through this sequence is mediated by molecular 
alterations that are thought to be induced by the chronic inflammation present 
in Barrett’s esophagus [3]. The transformation from a normal cell into a tumor 
cell is thought to require four to seven alterations, each of them leading to the 
induction of proteins involved in tumorigenesis or downregulation of proteins pro-
tecting the cell [4]. These alterations are usually comprised of genetic lesions or 
altered methylation patterns of genes, resulting in changes in mRNA and protein 
expression. In this review the focus will be on the molecular alterations that affect 
the subsequent processes during the metaplasia-dysplasia-carcinoma sequence: 
inflammation, intestinal metaplasia development, angiogenesis, cell proliferation, 
apoptosis, cell-cycle regulation, and cell-cell adhesion.
INFLAMMATION AND OXIDATIVE STRESS
Barrett’s esophagus is characterized by a chronic inflammation that is most likely 
the result of repeated gastroesophageal reflux. As with other chronic inflamma-
tory lesions, such as Helicobacter pylori induced gastritis and inflammatory bowel 
disease, Barrett’s esophagus also predisposes to cancer [1, 5-8]. The carcinogenic 
role of inflammation in Barrett’s esophagus is illustrated by the observation that 
anti-inflammatory drugs, such as aspirin, are able to (partially) protect against es-
ophageal adenocarcinoma [9]. The major components of gastroesophageal reflux 
are gastric acid, bile, and pancreatic enzymes. Their repetitive combined presence 
in the esophagus induces cell damage [10]. Damaged epithelial cells usually start 
to produce inflammatory mediators such as cytokines and chemokines, which 
leads to the attraction of inflammatory cells. These inflammatory cells produce 
reactive oxygen species and other free radicals to eliminate the exposed antigen, 
in this case the damaged cell [11]. The reactive oxygen species and other free 
radicals can damage the cell-membrane, which alters the membrane-permiability 
and the activity of membrane receptors. Moreover, these reactive oxygen species 
do not only affect the damaged cell but are also able to cause damage in the sur-
rounding cells. DNA mutations caused by reactive oxygen species occur at random 
and can be lethal. However, surviving cells can develop mutations that lead to the 
induction of genes involved in carcinogenesis (Figure 1) [12]. Increased amounts 
of reactive oxygen species have been observed in Barrett’s esophagus [13], and 
animal studies suggests that oxidative stress plays a role in the formation of an 
esophageal adenocarcinoma [14, 15]. 
  Several enzymes and other factors mediate scavenging of toxic oxygen and 
C
ha
pt
er
 2
14
Molecular biology of esophageal adenocarcinoma 15
other radicals. Enzymes such as gluthatione-S transferase, gluthatione peroxi-
dase, superoxide dismutase, catalase, vitamin C, and vitamin E catalyze a reac-
tion in which a toxic radical is converted into a less toxic compound. This catalysis 
prevents DNA damage and cancer cell formation. The glutathione-S transferase 
family of radical detoxifying enzymes comprises many isoforms, whose expres-
sion is gradually downregulated during the malignant progression of Barrett’s 
esophagus [16, 17]. Furthermore, inhibition of glutathione peroxidase secretion 
has been observed in this disorder [18]. The expression of superoxide dismutase 
was not changed during neoplastic progression [17], and catalase levels in Bar-
rett’s esophagus and esophageal adenocarcinoma are not yet determined. Plasma 
and tissue vitamin C levels, but not vitamin E levels were decreased in Barrett’s 
esophagus compared with normal squamous epithelium [19]. Although not all 
enzymes involved in detoxification of radicals are decreased in Barrett’s esopha-
gus and adenocarcinoma, overall scavenging capacity seems diminished during 
esophageal carcinogenesis.
   
INFLAMMATORY MEDIATORS
Upon injury caused by gastroesophageal reflux, the damaged esophageal cells will 
start to secrete inflammatory mediators such as cytokines and chemokines, and 
this leads to the migration of inflammatory cells to the damaged tissue. NF-κB is 
a transcription factor that is responsible for the upregulation of many pro-inflam-
matory cytokines and chemokines, and it has also been linked to several onco-
genic functions such as proliferation, metastasis and angiogenesis [20]. NF-κB is 
activated in response to the bile acid deoxycholic acid in a esophageal cell-culture 
model [21, 22]. Indeed activated NF-κB was present in about half of Barrett’s 
metaplasia and in most adenocarcinoma samples [21], indicating that reflux in-
duced NF-κB activation contributes to esophageal carcinogenesis.
Nucleus DNA
damage
Epithelial cell
Gastro-esophageal 
Reflux
damage
chemokines
cytokines
Inflammatory 
cell
ROS
ROS
Figure 1   Schematic rep-
resentation of the effect of 
gastroesophageal reflux on 
esophageal cells. The com-
ponents of gastroesophageal 
reflux damage the epithelial 
cells, as a consequence these 
cells will start to secrete in-
flammatory mediators such 
as cytokines and chemokines 
that attract inflammatory cells. 
These inflammatory cells pro-
duce reactive oxygen species 
(ROS) that can cause DNA 
damage in undamaged cells, 
thereby inducing tumor pro-
moting mutations.
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  The NF-κB regulated pro-inflammatory chemokine interleukin-8 (IL-8) attracts 
neutrophils, which are the most potent producers of reactive oxygen species. Us-
ing in vitro experiments it was demonstrated that expression of IL-8 is induced 
in esophageal cells by a brief exposure to the bile acid deoxycholic acid [22]. 
Expression of IL-8 but also of cytokine IL-1β is increased in Barrett’s esophagus 
[23]. This effect was most pronounced near the squamocolumnar junction. Dis-
tally, where most adenocarcinomas occur, expression of the anti-inflammatory 
cytokines IL-4 and IL-10 was observed [23, 24]. This suggest a tight balance be-
tween pro-inflammatory and anti-inflammatory agents in cancer development [3, 
25], but the exact chemokine and cytokine profiles in esophageal adenocarcinoma 
still have to be determined. Increased understanding of the role of chemokines 
and cytokines in esophageal adenocarcinoma is required for novel therapeutic 
interventions controlling expression of these chemoattractants.
  Neutrophils are frequently observed inflammatory cells in Barrett’s esophagus. 
These cells are attracted by the NF-κB induced chemokine IL-8, but the calpro-
tectin complex functions also in chemotaxis of these cells. The calprotectin com-
plex has been implicated in chronic inflammatory diseases, such as inflammatory 
bowel disease. In the esophagus, both subunits of the complex, calgranulin A and 
B have been shown to be associated with the development of high-grade dysplasia 
in Barrett’s esophagus [26] implicating a role for calprotectin and for neutrophils 
in the onset of neoplastic progression.
  Cyclooxygenase 2 (COX-2) is the rate-limiting enzyme in the conversion of 
arachidonic acid into prostaglandins. Prostaglandin E2 (PGE2) has many tumor-
promoting properties, such as inhibiting apoptosis, increasing proliferation and 
angiogenesis, and inducing the production of matrix metalloproteinases (see 
paragraph on cell-cell adhesion and Figure 2). COX-2 is inducible by a variety of 
factors, such as proinflammatory cytokines (TNF-α, TGF-β) and growth factors 
 
+
-
+ +
+
angiogenesisproliferation
apoptosis
Prostaglandins
TNF
IL-1
Arachidonic acid
COX-2
matrix degradation
Figure 2   The role of COX-2 
in malignant progression. Pro-
inflammatory cytokines such 
as IL-1 and TNF-α induce cy-
clooxygenase 2 (COX-2), which 
converts arachidonic acid into 
prostaglandins. These prosta-
glandins are capable of inhibiting 
apoptosis and inducing cell pro-
liferation, angiogenesis and loss 
of cell-cell adhesion by means of 
matrix metalloproteinase (MMP) 
upregulation.
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[27, 28]. It has been demonstrated using in vitro as well as in ex-vivo models 
for Barrett’s esophagus that COX-2 expression is induced by bile and acid [29, 
30], suggesting that gastroesophageal reflux induces expression of this enzyme, 
thereby promoting carcinogenesis. Indeed, increased COX-2 levels were observed 
in Barrett’s esophagus and adenocarcinoma [31]. Since COX-2 induces tumori-
genesis via several pathways, it is suggested that this enzyme is one of the key 
factors in esophageal carcinogenesis.
    
INTESTINAL PROTEINS
Barrett’s esophagus is characterized by the presence of intestinal metaplasia, and 
only this type of metaplasia predisposes to esophageal adenocarcinoma [32]. 
Several proteins that are normally expressed exclusively in intestinal tissue, are 
also present in Barrett’s esophagus. An example is CDX2, a transcription factor 
involved in intestinal differentiation, which functions in the development of intesti-
nal epithelium [33]. As Barrett’s esophagus is defined as a replacement of normal 
esophageal epithelium by intestinal-like epithelium, CDX2 has been suggested 
to play an important role in the development of this lesion [34, 35]. Although a 
tumor-suppressor function has been suggested for CDX2 [36], in the esophagus 
this is unlikely since loss of CDX2 expression was only observed in few adenocar-
cinomas [35]. 
  CDX2 is responsible for the transcription of several intestinal-specific genes, 
such as MUC2. Mucins are large glycoproteins that are key components of the mu-
cus layer on epithelium. This layer protects the epithelium from mechanical and 
chemical damage. Mucins are divided into two groups; i) the membrane bound, 
and ii) the secreted mucins [37]. Each tissue type has its own characteristic mucin 
pattern and this pattern changes during metaplastic and neoplastic progression 
[38]. The predominant mucins in Barrett’s esophagus are MUC2, MUC5AC and 
MUC6 [39, 40]. In high-grade dysplasia, MUC4 expression is upregulated [41], 
whereas in adenocarcinoma MUC1 expression is upregulated and MUC2, MUC5AC 
and MUC6 expression is downregulated [39]. The role of these changes in mucin 
expression is unknown. However, it can be hypothesized that the carbohydrate 
structures of overexpressed MUC1 and MUC4 mask tumor antigens, thereby inhib-
iting the recognition and clearance of tumor cells by the immune system [42].
ANGIOGENESIS
Barrett’s esophagus is highly vascularized tissue, and the presence of microves-
sels gives the Barrett’s tissue its characteristic salmon pink color. This vasculariza-
tion is necessary for the recruitment of immune cells. However, the formation of 
new blood vessels, angiogenesis, is also essential in tumors for nutrient delivery, 
since rapidly proliferating cells need an excess of nutrients, which cannot be pro-
vided by the surrounding tissue. Without the supply of nutrients, the tumorcells 
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cease proliferation [43].  Furthermore, the proximity of abundant blood and lymph 
vessels enables tumorcells to rapidly metastasize.
  Vascular endothelial growth factor (VEGF) is an important mediator of blood ves-
sel growth. VEGF expression has been observed in goblet cells in Barrett’s esopha-
gus [44] and increases during the development of esophageal adenocarcinoma 
[45]. Furthermore, mRNA levels of fibroblast growth factor (FGF), another growth 
factor involved in microvessel formation, also increased during adenocarcinoma 
development [46]. COX-2 metabolites have many roles in angiogenesis. Prostag-
landins E2 and I2 induce VEGF and FGF, regulate branch formation, and enhance 
the expression of MMPs that degrade the extracellular matrix, which promotes the 
growth of vessels [47]. 
  The induction of angiogenesis is probably an relative early process in esopha-
geal adenocarcinoma formation, since most precursor lesions are already highly 
vascularized. This means that reducing angiogenesis is a good approach for the 
prevention of adenocarcinoma development. 
 
INCREASED PROLIFERATION
Tissue damaged by gastroesophageal reflux will start to proliferate in order to 
replace the damaged cells by new ones. When this proliferation gets out of con-
trol, neoplastic lesions will appear. Proliferation is mediated by three groups of 
proteins: extracellular growth factors, their receptors, and the proteins involved 
in intracellular signalling that will eventually lead to proliferation. 
  Tissue damage results in the induction of growth factors. These factors will 
bind to their receptors and transduce the growth signal to an intracellular sig-
nalling pathway that will eventually lead to proliferation. Aberrant expression of 
epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) has 
been reported in Barrett’s esophagus, dysplasia and esophageal adenocarcinoma 
[48, 49]. Another growth factor receptor that resembles EGFR is c-ErbB-2, which 
is considered to be an orphan receptor since no ligand has yet been identified 
[50]. Aberrant c-ErbB-2 expression has been observed in approximately 10% of 
low-grade dysplasia, 20% of high-grade dysplasia and 30% of adenocarcinoma 
samples [51, 52]. These growth factors and their receptors in the damaged es-
ophageal epithelium probably function in wound healing, but an increase in their 
levels could also contribute to the uncontrolled proliferation that is involved in 
neoplastic transformation.
  Many oncogenes are responsible for the intracellular signalling that will lead to 
proliferation. Wnt-signalling is involved in the transcription of oncogenes such as 
c-myc and cyclin D1. This signalling pathway is outlined in Figure 3. The main 
component of the Wnt-pathway is β-catenin. Normally, β-catenin forms a com-
plex with E-cadherin (see paragraph on cell-cell adhesion). Cytosolic β-catenin is 
captured in a complex with APC, axin, and other proteins.This results in the phos-
phorylation of β-catenin leading to its proteolytic degradation. Binding of Wnt to 
the frizzled receptor inhibits the complex formation, and free β-catenin is allowed 
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to enter the nucleus where it enhances transcription of several oncogenes [53]. 
Defects in the proteins that form the inhibitory complex will lead to increased nu-
clear translocation of β-catenin. 
  In Barrett’s esophagus and esophageal adenocarcinoma, hypermethylation of 
the APC promoter occurs [54]. This probably leads to decreased APC transcription. 
Loss of axin expression has not been observed in Barrett’s esophagus and esopha-
geal adenocarcinoma [55]. This means that hypermethylation of the APC promoter 
seems the most important mechanism for β-catenin induction and nuclear trans-
location. Indeed, nuclear translocation of β-catenin was observed in dysplastic 
Barrett’s esophagus and adenocarcinoma [56, 57]. Increased nuclear β-catenin 
levels enhance expression of the c-myc oncogene. C-myc overexpression was ob-
served in Barrett’s esophagus and adenocarcinoma [58, 59], and overexpression 
of other genes, thereby preventing apoptosis and increasing proliferation. Clearly 
components of the Wnt-pathway are involved in esophageal carcinogenesis, and 
prevention of nuclear β-catenin translocation may form a good option in order to 
prevent neoplastic progression.
frizzled
Wnt
E-cadherin
-catenin
-catenin
APC
axin
Proteolytic 
degradation
-catenin
Oncogene 
transcription
P
P
Figure 3   Schematic representa-
tion of the Wnt-pathway. Normally, 
β-catenin forms a complex with E-ca-
dherin. Cytosolic β-catenin is captured 
in a complex with APC and axin, and 
other proteins. This results in phosp-
horylation of β-catenin leading to its 
proteolytic degradation. Binding of 
Wnt to the frizzled receptor inhibits 
the complex formation, and free β-
catenin is allowed to enter the nucleus 
where it enhances transcription of se-
veral oncogenes.
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ESCAPE OF APOPTOSIS
Apoptosis is a mechanism of programmed cell-death that eliminates injured cells 
or cells that otherwise function abnormally. Regulation of apoptosis requires a del-
icate balance between different groups of proteins. First of all, apoptosis is accom-
plished through a cascade of several caspase proteins. This cascade is regulated 
by different stimuli, which are all activated through specific pathways. A range of 
specific death receptors, all having their own ligands, function to activate these 
caspases. Examples of these death receptors are Fas (CD95) and Fas-ligand, and 
TNF receptor and TNF-α [60]. Furthermore, the Bcl family of proteins play impor-
tant roles in the induction and inhibition of apoptosis. Well-known members of this 
family are Bax (pro-apoptotic), Bcl-2 and Bcl-XL (anti-apoptotic). Bax induces mi-
tochondrial cytochrome C release, which triggers the caspase cascade. Induction 
of Bax is mediated by the tumor-suppressing protein p53, whereas it is inhibited 
by Bcl-2 and Bcl-XL (Figure 4)[61].
 
+
+ +
+
+
+-
TNF
apoptosis
Caspases
Cytochrome C 
Bax
TNFR
FasL
Fas
Bcl-2
Bcl-XL
p53
Figure 4   Signals involved in apopto-
sis. Binding of ligands TNF-α and FasL 
to their specific death receptors TNF 
Receptor (TNFR) and Fas, respectively, 
induce a caspase cascade that will 
drive the cell into apoptosis. This cas-
cade is also activated by cytochrome 
C, which is regulated by members of 
the Bcl family proteins such as Bax, 
Bcl-2, and Bcl-XL, and p53.
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  Disruption of these pathways will lead to prolonged survival of damaged cells, 
which will lead to tumorigenesis. However, the role of apoptosis inhibition in ad-
enocarcinoma development is pivotal. The Bax and Bcl-2 ratio is pro-apoptotic 
during malignant progression [41, 62], whereas Bcl-XL protein is increased along 
the metaplasia-dysplasia-adenocarcinoma pathway [63, 64], and thus has an 
anti-apoptotic effect. In contrast, Fas-ligand is overexpressed in dysplasia and ad-
enocarcinoma, which leads to induction of apoptosis [65, 66]. However Fas-ligand 
could also be produced to kill lymphoid cells and thereby prevent the immune sys-
tem from recognizing and eliminating the tumor cells [67]. Fas expression seems 
to compensate for this proapoptotic effect by showing decreased expression in 
dysplasia and adenocarcinoma [68, 69]. Although these data are conflicting, it 
was recently suggested that Barrett’s esophagus is relatively resistant to apopto-
sis [70], which can promote the outgrowth of mutated esophageal cells. 
  Another way for a tumor cell to escape apoptosis is to overexpress the enzyme 
telomerase, which is a ribonucleoprotein that prevents telomere shortening. Te-
lomere shortening limits the number of times that a cell can divide. Inhibition of 
this process extends the life-span of a cell and represses apoptosis [71]. Telomer-
ase expression increases during the different developmental stages of esophageal 
adenocarcinoma [72, 73], thus preventing the cell to go into apoptosis.
LOSS OF CELL-CYCLE CONTROL
A replicating cell progresses through the cell-cycle, consisting of the G1-phase, 
the S-phase (DNA synthesis), the G2 phase, and the M-phase (mitosis) (Figure 5). 
+
+
+
-
-
-
G1
S
p53
p16
p21
p27
Cdk4
Cdk6
Cyclin D1
Cdk2
Cyclin E1
pRb
P
pRb
P
P
pRb
PPP
G2
M
G0
Figure 5   Schematic representation of the cell-cycle (left) and factors involved in progression of the 
cell-cycle to the S phase (right). One of the key regulators in this process is the Retinoblastoma protein 
(pRb). Complexes of cyclin D1 with CDK4/6, and Cyclin E with CDK2 phosphorylate pRb. These complexes 
are inhibited by p16 (CDKN2), p21, p27kip, and p53. Phosphorylated pRb enables the cell to progress to 
the S-phase, and is thus crucial for tumor development.
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Most cells escape from the cell-cycle in the G1 phase and are in a resting phase 
(G0). For proliferation the cell has to progress from the G1 to the S-phase. The 
progression of the cell cycle is regulated by a variety of proteins, such as cyclins 
and cyclin dependent kinases (Figure 5). Various cyclin dependent kinases (Cdks) 
form complexes with cyclins. Progression to a new stage in the cell cycle requires 
the action of one or more cyclin-Cdk-complexes. One of the key regulators in this 
process is the Retinoblastoma protein (pRb). Unphosphorylated pRb binds to the 
E2F family of transcription factors, thereby inhibiting the transcription of genes 
leading to progression to the S-phase, such as cyclin A and cyclin E [74]. The cy-
clin D1 and CDK4/6, and cyclin E and CDK2 complexes both phosphorylate pRb. 
p16 (CDKN2), p21, and p27kip  are small proteins that inhibit these CDK/cyclin 
complexes, which will decrease the pRb phosphorylation (Figure 5).
  For uncontrolled proliferation to occur, it is required that the cell progresses 
to the S-phase, so abnormalities in proteins that control this progression are 
frequently observed in carcinogenesis. Accumulation of mutant pRb during the 
development of adenocarcinoma has been reported [75], there is however no 
information on the exact pRb phosphorylation state during malignant progression 
of Barrett’s esophagus. There may however be an increased proliferation state 
in Barrett’s esophagus, as increased cyclin D1 expression has been reported in 
Barrett’s esophagus and adenocarcinoma [76]. Furthermore, inactivating altera-
tions in the inhibitors of pRb phosphorylation, p16, p27kip, and p21 will lead to 
increased pRb phosphorylation and progression of the cell cycle. Inhibition of p16 
by promoter hypermethylation was a frequently occurring event [77, 78], and 
cytoplasmic staining of abnormal p27kip was observed in adenocarcinoma, while 
in non-dysplastic Barrett’s esophagus and in dysplasia staining was predominantly 
nuclear [79]. Furthermore, in p27kip knockout mice that underwent gastrectoje-
junostomy to induce columnar-like epithelium in the esophagus, adenocarcinoma 
was observed more frequently than in wild-type mice [80]. 
  The extensively studied tumor-suppressor gene p53 is involved in the inhibition 
of many tumor-promoting processes, such as DNA repair and apoptosis, and is 
sometimes called “the guardian of the genome”. p53 is an activator of p21 and thus 
inhibiting pRb phosphorylation (Figure 5). Accumulation of mutant p53 protein 
occurs frequently in high-grade dysplasia and adenocarcinoma, but also in non-
dysplastic Barrett’s esophagus and low-grade dysplasia, although less frequently 
[81-83]. Several reports suggest that p53 is actively involved in the progression 
from dysplasia to esophageal adenocarcinoma [81, 84]. Interestingly, while p53 
is involved in the transactivation of p21, p21 itself seems to be upregulated in a 
p53-independent manner in Barrett’s esophagus and esophageal adenocarcinoma 
[85, 86]. These alterations in this intricate network of interacting factors suggest 
that during esophageal adenocarcinoma development, cells progressively lose cell 
cycle control. However, it is still unclear which factors initiate this process.
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LOSS OF CELL-CELL ADHESION
Inflammatory cells need to penetrate into damaged tissue in order to allow them 
to contact and eliminate their targets. This means the tightly associated epithelial 
cells should be loosened to allow passage of the inflammatory cells. However, 
intimate cell-cell contact also plays an important role in preventing the develop-
ment of malignancies, as contact with a neighbouring cell also serves to inhibit 
proliferation. When cell-cell interactions are reduced, this contact inhibition will 
decrease and the cell is allowed to proliferate in an uncontrolled fashion. Moreo-
ver, when the cells are relatively loosely attached to each other, it is easier for 
tumor mass to invade neighbouring tissues, and for tumor cells to metastasize via 
lymph or blood vessels.
  The main proteins involved in cell-cell adhesion are E-cadherin and β-catenin 
[87]. These proteins form a complex in which in which β-catenin attaches to the 
cytoskeleton, and E-cadherin is located on the cell-surface so that it can bind to 
the E-cadherin molecules on the surface of neighbouring cells. The pro-inflamma-
tory cytokine TNF-α is produced by inflammatory cells and mediates phosphoryla-
tion of the β-catenin-E-cadherin complex. These phosphorylated complexes have 
a decreased affinity for E-cadherin molecules on other cells and phosphorylation 
enhances its degradation [88]. In Barrett’s esophagus, E-cadherin levels decrease 
along the metaplasia-dysplasia-carcinoma sequence [56, 57, 89]. Moreover, in-
creased phosphorylation of β-catenin will result in higher nuclear levels of this 
protein, which induces the wnt-signalling pathway, thus enhancing proliferation 
rates (see paragraph on increased proliferation).   
  Other proteins that promote cellular detachment are the matrix metalloprotein-
ases (MMPs). These are enzymes that degrade the extracellular matrix, thereby 
allowing for the influx of immune cells, but also enhancing the migration and me-
tastasis of tumor cells [90]. MMPs are induced by prostaglandin E2, a compound 
that is also induced by inflammation (Figure 2). Increased MMP-7 and MMP-12 
expression is associated with Barrett’s esophagus, whereas increased MMP-1, 
MMP-2, and MMP-9 expression with esophageal adenocarcinoma [91, 92].
  In a Barrett’s adenocarcinoma metastasis is a frequently occuring and early 
process. It is suggested that the chronic inflammation present in Barrett’s es-
ophagus influences this process, thus any therapeutic option that would decrease 
the ongoing inflammation might prove beneficial in the prevention of esophageal 
adenocarcinoma.
  
  
CLINICAL IMPLICATIONS
Understanding the molecular alterations that occur during development of es-
ophageal adenocarcinoma will provide new insights for the diagnosis, prevention 
and treatment of this neoplasm. Various molecular alterations that mark the pres-
ence of dysplasia or adenocarcinoma have been suggested as molecular markers 
for the early detection of these lesions. However, p53 accumulation is until now 
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the only alteration that has been associated with progression to a more malignant 
phenotype in the sequence Barrett’s esophagus, dysplasia and finally adenocar-
cinoma [93]. 
  The standard therapy for the prevention of adenocarcinoma development in Bar-
rett’s esophagus is treatment with proton-pump inhibitors, which mediates acid 
suppression. In biopsies of Barrett’s esophagus, proliferation was reduced, while 
differentiation was induced after treatment with a proton pump inhibitor [94]. 
However, it is still debatable if acid suppression alone can prevent the develop-
ment of adenocarcinoma, since bile is also an important cause of reflux-induced 
damage to the esophagus [95]. 
  Commonly used drugs such as non-steroidal anti-inflammatory drugs (NSAIDs), 
aspirin and COX-2 inhibitors have been suggested to prevent the development of 
esophageal adenocarcinoma [9], but large-scale clinical trials have not yet been 
performed. NSAIDs, aspirin, and COX-2 inhibitors are involved in the reduction of 
inflammation. They suppress NF-κB activation, thereby inhibiting the expression 
of NF-κB regulated cytokines and cyclin D1 [93]. COX-2 is also involved in several 
oncogenic processes. COX-2-inhibitors reduced proliferation in Barrett’s esopha-
gus [96, 97], decrease microvessel formation [98], and inhibit the nuclear trans-
location of β-catenin thereby suppressing the transcription of several oncogenes 
[53]. Therefore, COX-2 inhibitors have been suggested to be the most promising 
chemopreventive agents for the prevention of esophageal adenocarcinoma devel-
opment. 
  Currently, several new agents for the treatment of esophageal cancer are under 
development. Iressa is a potent inhibitor of EGFR that shows promising results 
in the treatment of small-cell lung cancer [99]. Furthermore, the telomerase 
inhibitor PPA has been demonstrated to induce growth arrest and apoptosis in 
an esophageal adenocarcinoma cell line [100]. These inhibitors can provide new 
therapeutic options for the treatment of esophageal adenocarcinoma. 
CONCLUSIONS
The accessability of esophageal tumors by endoscopy makes it relatively easy to 
study the molecular changes that occur during carcinogenesis. However, the lack 
of well-described in vitro or animal models for esophageal adenocarcinoma com-
plicates the conduction of functional studies. Many of the molecular alterations 
have been described, but they have not been connected to a functional sequence 
in which they occur, and it is still not clear which alteration at what time will initiate 
tumogenesis. Most likely, various molecular changes occurring at the same time 
eventually determine whether adenocarcinoma will occur. The abnormalities that 
are identified fit in the well-known models of carcinogenesis, describing increased 
proliferation, loss of cell cycle control, escape of apoptosis, loss of cell-cell adhe-
sion, and angiogenesis as the main processes that will lead to tumor formation 
[43]. However, excessive activation of the immune system also plays an important 
role in carcinogenesis. The chronic inflammation present in Barrett’s esophagus, 
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which is already metaplastic tissue, can form the trigger for further damage lead-
ing to the development of dysplasia. As severity of dysplasia progresses, the 
damaging effect of inflammation will be less inportant, because the molecular 
alterations present at that stage will cause further changes, that eventually will 
result in the development of esophageal adenocarcinoma (Figure 6).
  The understanding of the molecular processes underlying the development of 
esophageal adenocarcinoma will provide markers for the detection of early ma-
lignant lesions, such as high-grade dysplasia. New molecular techniques, such 
as microarray analysis will allow the identification of abnormal gene expression 
for many genes at once. Furthermore, with the elucidation of molecular changes 
during esophageal carcinogenesis, new targets for anti-tumor therapy have been 
identified. This will lead to the development of new therapeutic possibilities that 
will increase the survival of patients with esophageal adenocarcinoma. 
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Figure 6   The effect of inflammation on molecular changes in esophageal adenocarcinoma development. 
Under influence of gastroesophageal reflux the normal squamous epithelium is damaged and replaced by 
columnar epithelium of the intestinal type, which is called Barrett’s esophagus. The damaged cells secrete 
inflammatory mediators such als cytokines and chemokines that will attract inflammatory cells. These 
cells produce reactive oxygen species that can cause DNA damage. This DNA damage leads to molecular 
alterations and the tissue can progress to dysplasia and esophageal adenocarcinoma. These molecular 
alterations are involved in inflammation, intestinal protein expression, angiogenesis, proliferation, apop-
tosis, cell-cycle control, and cell-cell adhesion.
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Chapter 3
The homeodomain protein CDX2 is an 
early marker of Barrett’s esophagus
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ABSTRACT
Background: Barrett’s esophagus (BE) is defined by the replacement of squa-
mous epithelium by specialized intestinal epithelium (SIE). Transcription factors 
associated with normal intestinal differentiation may be involved in the develop-
ment of BE. One of the key regulators of intestinal differentiation is thought to 
be CDX2. To evaluate if CDX2 is involved in the development of BE, expression of 
CDX2 was determined in BE, in squamous epithelium and adenocarcinoma of the 
esophagus.
Methods: CDX2 expression was assessed in 245 samples from the esophagus. 
These consisted of 167 biopsies of the columnar lined segment and 38 squamous 
epithelial biopsies of 39 patients with histologically confirmed BE, of whom 10 also 
had an adenocarcinoma. In addition, 40 biopsies of 20 patients with reflux es-
ophagitis without BE were evaluated. The presence of CDX2 protein was detected 
by immunohistochemistry in 138 formalin-fixed paraffin-embedded biopsies of 16 
patients with BE, 4 patients with an esophageal adenocarcinoma and 20 patients 
with reflux esophagitis. Semi-quantitative detection of CDX2 and MUC2 mRNA 
was performed by RT-PCR on RNA isolated from 88 snap frozen biopsies of BE and 
squamous epithelium of 19 patients with BE, and when present from esophageal 
adenocarcinoma. 
Results: In 53/79 biopsies taken from the columnar lined segment SIE was 
present, in which CDX2 protein was observed in all epithelial cells. However, CDX2 
protein was not observed in biopsies containing only gastric metaplastic epithe-
lium (26/79), or in squamous epithelium (0/40) of patients with reflux esophagitis 
(p<0.001). CDX2 mRNA was detected in all biopsies with goblet cell specific MUC2 
transcription, which is indicative for the presence of SIE. Low levels of CDX2 mRNA 
were also observed in 6/19 squamous epithelium samples taken 5 cm above the 
squamo-columnar junction of patients with BE. 
Conclusion: CDX2 protein and mRNA are strongly associated with the presence 
of SIE in the esophagus. As CDX2 mRNA was also present in one-third of BE pa-
tients with endoscopically normal appearing squamous epithelium, expression of 
CDX2 may precede morphological changes observed in BE. Therefore, pathways 
involved in the induction of CDX2 transcription in squamous epithelial cells are 
likely to play a role in the development of Barrett’s esophagus.
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INTRODUCTION
Barrett’s esophagus (BE) is a complication of chronic gastro-esophageal reflux 
disease (GERD). Although 20-30% of the Western population has regular GERD-
related complaints [1], it is poorly understood why only 3-5 % of these patients 
develop long segment BE [2]. BE has a prevalence of 0.03% in the Western popu-
lation [3] and its development in patients with GERD is associated with obesity at 
a young age [4], increased duodeno-gastro-esophageal reflux [5, 6], complaints 
at an earlier age [5], a familiar predisposition [7], and a combination of obesity, 
presence of a hiatal hernia and male gender [6]. Patients with BE have an in-
creased risk of developing adenocarcinoma in the esophagus with an annual inci-
dence of 0.5% per year [8]. Once these patients have developed adenocarcinoma, 
the prognosis is poor with a 5-year survival rate of 5-20% [9].
  BE is characterized by the metaplastic replacement of squamous epithelial cells 
of the lower part of the esophagus by specialized intestinal epithelium (SIE), 
which is associated with the presence of goblet cells and the expression of intes-
tinal markers such as MUC2 [10], alkaline phosphatase [11], villin [12], and su-
crase-isomaltase [13]. The genetic events responsible for this process are largely 
unknown. 
  Transcription factors, which play an important role in normal intestinal differen-
tiation, may also play a role in the development of SIE in the esophagus. CDX2 
is such a transcription factor, and belongs to the caudal-related homeobox gene 
family[14]. CDX2 expression in the gastrointestinal tract is intestine-specific, with 
a tightly regulated anterior boundary in the duodenum [15]. CDX2 is involved in 
early differentiation and maintenance of intestinal epithelial cells, characterized by 
the formation of multilayered structures with microvilli [14]. CDX2 also induces 
intestine-specific transcription of the genes encoding MUC2, alkaline phosphatase 
and sucrase-isomaltase [14, 16-18]. Therefore, CDX2 is considered to be an im-
portant factor in the development and differentiation of intestinal epithelium [19, 
20].
  As BE is characterized by the development of SIE in the esophagus, CDX2 may 
also play a role in the development of BE. To investigate if CDX2 expression is 
associated with BE and if its expression may precede the morphological changes 
observed in BE, we determined its expression in columnar epithelium of patients 
with BE, in squamous epithelium of patients with reflux esophagitis only, and in 
esophageal adenocarcinoma. Here, we demonstrate that CDX2 is expressed in 
SIE, but not in squamous epithelium of patients with reflux esophagitis and in 
gastric metaplastic epithelium. Furthermore, CDX2 mRNA was also detected in 
squamous epithelium of one-third of patients with BE, suggesting that CDX2 is 
indeed involved in the development of BE and that its expression may precede 
morphological changes observed in BE. 
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MATERIALS AND METHODS
Patients and Materials
CDX2 expression was analyzed in 245 esophageal samples. These consisted of 
167 biopsies of the columnar lined segment and 38 squamous epithelial biopsies 
of 39 patients with histologically confirmed BE, of whom 10 also had an esopha-
geal adenocarcinoma, and 40 biopsies of 20 patients with reflux esophagitis with-
out BE.
  In 138 biopsies, consisting of  79 biopsies of the columnar lined segment, 19 
esophageal adenocarcinoma, and 40 squamous epithelium biopsies of the es-
ophagus, CDX2 protein was detected by immunohistochemistry (Table 1). The 
four quadrant biopsies taken at 2 cm intervals from the columnar lined segment 
were pooled, formalin-fixed, and paraffin-embedded. Biopsies of the colon were 
used as a positive control. 
Table 1. Patient characteristics
Patient characteristics patients biopsies age
mean (SD)
male
%
First group 
IHCa Adenocarcinoma  4 19 78.5 (2.7) 75%
Barrett’s esophagus 16 79 70.8 (14) 66%
Reflux esophagitis 20 40 61.8 (11.6) 71%
Second group
RT-PCRa Adenocarcinoma 6 12 68.9(11.5) 57%
Barrett’s esophagus 19 76 65.1(15.1) 55%
a Abbreviations used: IHC, immunohistochemistry; RT-PCR, reverse transcriptase PCR.
  Biopsies from a second group of patients, not related to the first group, were 
used for mRNA analysis, as this analysis could not be performed on the forma-
lin-fixed paraffin embedded samples. One-hundred and seven esophageal biop-
sies were collected at endoscopy from 19 patients with BE (Table 1), of whom 6 
patients also had esophageal adenocarcinoma. Biopsy specimens were obtained 
from the columnar mucosa of the esophagus (n=38), the adenocarcinoma if 
present (n=12), and the squamous epithelium 5 cm above the neosquamous-co-
lumnar junction (n=38). For each of these locations, the biopsies of each location 
(2 of the BE segment, 2 of the squamous epithelium, and when present 2 of the 
esophageal adenocarcinoma) of individual patients were pooled, snap frozen and 
used for RNA extraction (see below). An additional biopsy was taken next to the 
previous biopsies from the BE-segment, and was used for the histological evalu-
ation of the presence of SIE (n=19). All columnar segments lining the esophagus 
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at endoscopy of both groups of patients had a length of 3 cm or more. Biopsies of 
the colon were used as positive control for CDX2 mRNA. The study was approved 
by the Central Committee on Research Involving Human Subjects in The Nether-
lands in 2002.
Histological analyses
Sections from the biopsies and part of the biopsies taken for RNA analysis, were 
stained with haematoxylin and eosin (H&E) and evaluated for the presence of SIE 
and/or adenocarcinoma. Alcian blue at pH 2.5 staining was performed to facilitate 
the detection of mucin producing goblet cells [21]. The inflammatory response in 
biopsies of patients with reflux esophagitis and BE, which were used for immuno-
histochemistry, was graded by the Ismail-Beigi classification [22] for squamous 
epithelium and by the updated Sydney system [23, 24] for columnar epithelium. 
Immunohistochemistry
Biopsy samples were serially sectioned at 4 μm, mounted on adhesive slides, 
dried overnight at 37 °C, and deparaffinized with xylene. Antigen retrieval was 
performed in 10 mM monocitric acid at pH 6.0 at 100 °C for 15 min. After cooling, 
the samples were blocked with non-immune serum for 30 minutes. The sections 
were stained using the primary antibody against CDX2 (1:100 diluted; Biogenex, 
San Ramon, USA), followed by the addition of a biotinylated rabbit secondary 
antibody (DAKO, Glostrup, Denmark) and streptavidin-alkaline phosphatase com-
plex (DAKO, Glostrup, Denmark). A red color was developed using new-fuchsin 
substrate.
Semiquantitative RT-PCR
Total RNA was isolated using TRIzol-reagent (Invitrogen, Groningen, The Neth-
erlands), and remaining chromosomal DNA was subsequently removed with 
the DNA-free RNA kit (Zymo, Orange, USA). Semiquantitative reverse tran-
scription (RT)-PCR was performed using the intron-spanning primers CDX2 
5’-CCCAGCGGCCAGCGGCGAAACCTGT / 5’-TATTTGTCTTTTGTCCTGGTTTTCA and 
MUC2 5’-CAGGATGGCGCCTTCTGCTA / 5’-ATGCTGCTCCAAGCTGAGGT. Levels of 
CDX2 and MUC2 mRNA were standardized to levels of β-actin using the primers 
β-actin 5’-CAAGGCCAACCGCGAGAAG / 5’-CAGGGTACATGGTGGTGCC. cDNA was 
synthesized with the use of avian myeloma virus reverse transcriptase (Promega, 
Madison, USA). Primers were annealed by cooling down from 70°C to room tem-
perature, followed by cDNA synthesis by incubation for 30 min at 42°C. PCR-re-
actions (total volume of 25 μl) contained 1 μl of the cDNA solution, 1× PCR-core 
buffer (Promega), 2 mM MgCl2, 0.4 μM forward and reverse primer, 200 μM of 
each nucleotide (Promega) and 0.02 U/μl Taq polymerase (Promega). PCR condi-
tions were 35 cycles at 94°C (30 s); 55°C (30 s) and 72°C (1 min). PCR-products 
were size-separated on a 2% agarose gel and stained with ethidium bromide. 
Band size and intensity were determined with the Kodak 1D software version 3.5 
(Kodak, Rochester, USA). Bands were standardized against a housekeeping gene, 
β-actin, as described previously [25].
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Statistical analyses
All continuous variables were expressed as mean ± SEM. Statistical analyses were 
done by using the Fisher’s exact test for immunohistochemistry and the Mann 
Whitney U test for the semi-quantitative RT-PCR data. A two-sided p-value <0.05 
was considered statistically significant.
RESULTS
Histology
SIE was observed in 53/79 (67%) of the biopsies from the columnar lined segment 
and was absent in 26 (33%) biopsies. The biopsies without SIE existed of gastric 
type (cardiac or fundic-type) epithelium. SIE was also absent in all 40 reflux es-
ophagitis biopsies, which contained only squamous epithelium in all biopsies. 
  The inflammatory response in BE was graded according to the updated Sydney 
system, in which the inflammation is divided in four categories based on a acute 
component (numbers of neutrophils and eosinophils) and a chronic component 
(mononuclear cell count) in the epithelium [24]. This system was originally de-
veloped for glandular epithelium of the stomach, but has also been shown to be 
useful in the inflammatory classification of BE [24]. The acute component of in-
flammation in BE samples ranged from mild to severe in the majority of biopsies, 
with four BE patients showing a grade 1, seven BE patients a grade 2, and five BE 
patients a grade 3 inflammation, according to the updated Sydney classification 
(Table 2). The chronicity of the inflammation ranged from mild to severe, with 
five BE patients showing a grade 1, seven patients showing a grade 2, and four 
BE patients showing a grade 3. The inflammation in the 40 squamous epithelium 
biopsies of the 20 patients with reflux esophagitis was graded as grade 1 in seven 
patients, grade 2 in seven patients and grade 3 in six patients, according to the 
Table 2. Histological classification of inflammation 
Reflux esophagitis Barrett’s esophagus
Histological classification Histological classification 
Ismail-Beigi a n=20 Updated Sydney b n=16
Acute Chronic
1 7/20 (35%) 1 4/16 (25%) 5/16 (31%)
2 7/20 (35%) 2 7/16 (44%) 7/16 (44%)
3 6/20 (30%) 3 5/16 (31%) 4/16 (25%)
4 0 0
a Scored according to reference [22]
b Scored according to reference [24]
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Ismail-Beigi classification (Table 2). For this reason, we assumed that the biopsies 
were representative for the whole spectrum of inflammation in both BE and reflux 
esophagitis. 
CDX2 expression
All esophageal biopsies (53 SIE, 26 gastric type, 19 esophageal adenocarcinoma, 
and 40 inflamed squamous epithelium) were analyzed for presence of CDX2 pro-
tein by immunohistochemistry. All 53 biopsies with SIE had a positive nuclear 
stain for CDX2 of the epithelium (Figure 1A). This staining was associated (p< 
0.001) with the presence of goblet cells, as detected in serially sectioned slides 
with Alcian Blue at pH 2.5 staining (Figure 1B). Nuclear CDX2 expression was also 
observed in all 19 esophageal adenocarcinoma samples (Figure 1C). Cytoplasmic 
staining of CDX2 was not observed in any of the samples. Nuclear or cytoplasmic 
staining of CDX2 protein was absent in the 26 gastric type epithelium biopsies and 
in 40 squamous epithelium biopsies (Figure 1D). 
A B
C D
Figure 1   CDX2 protein in Barrett’s esophagus, esophageal adenocarcinoma, and reflux esophagitis. (A) 
A positive nuclear stain (red) for CDX2 was observed in 16/16 samples of Barrett’s esophagus. A repre-
sentative slide of patient 10 is shown. (B) The presence of CDX2 was associated with goblet cells, which 
are characteristic of Barrett’s esophagus, as was shown in an Alcian Blue at pH 2.5 stain of a serially 
sectioned slide of the same patient. (C) CDX2 was also present in 4/4 adenocarcinomas, which can be 
seen in a slide of patient 3. (D) CDX2 was absent in the squamous epithelium of all patients with reflux 
esophagitis (0/20). A color version of this figure is printed on page 113.
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Molecular analysis
Presence of CDX2 mRNA was evaluated in the second group of 19 patients with BE 
by RT-PCR, and this was normalized for β-actin transcript levels (Figure 2a). For 
all 19 patients, the presence of SIE was confirmed in the biopsies taken adjacent 
to those used in the transcriptional analysis. CDX2 mRNA was detected in 13/19 
BE segments and in 4/6 esophageal adenocarcinomas (Figure 2b). The levels of 
CDX2 mRNA did not significantly differ between BE and esophageal adenocarci-
noma (p=0.9) (Figure 2b).
  In order to determine if expression of CDX2 precedes the morphological changes 
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Figure 2   CDX2 mRNA in Barrett’s 
esophagus, squamous epithelium and 
esophageal adenocarcinoma. (A) CDX2 
mRNA was detected by RT-PCR (95 bp 
fragment) in 4/6 esophageal adenocar-
cinoma (ADC) samples, in 13/19 Bar-
rett’s esophagus (BE) samples, in 6/19 
squamous epithelium (Sq) samples and 
in colon control tissue (Co). (B) Relative 
mRNA levels of CDX2 in squamous epi-
thelium, BE and esophageal adenocarci-
noma. Levels of CDX2 mRNA were nor-
malized against β-actin. The mean CDX2 
mRNA levels in squamous epithelium 
(n=6) were significantly lower than the 
levels observed in BE (n=13) (p<0.01). 
The relative mRNA levels of CDX2 did not 
differ significantly between BE (n=13) 
and esophageal adenocarcinoma (n=4) 
(NS: p<0.1).
seen in BE, levels of CDX2 mRNA were also determined in squamous epithelium 
biopsies obtained five cm above the neosquamous-columnar junction of patients 
with BE (Figure 3). Low levels of CDX2 mRNA were present in 6/19 (32%) sam-
ples of squamous epithelium (Figure 3). The relative levels of CDX2 mRNA in the 
squamous epithelium were significantly lower (p≤ 0.01) than those observed in 
BE tissue (Figure 2b). The presence of goblet cells, characteristic for BE, was 
evaluated by the detection of goblet cell specific MUC2 mRNA. CDX2 mRNA was 
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present in all MUC2 positive samples. Furthermore, samples without the presence 
of CDX2 mRNA did not have MUC2 transcription. In only three BE samples with 
CDX2 transcription,  MUC2 mRNA was absent (Figure 3).  MUC2 transcripts were 
also not detected in any of the squamous epithelium samples.
DISCUSSION
In this study, we demonstrated that CDX2 protein was present in BE containing 
SIE, as was recently reported by others in BE [26, 27]. CDX2 expression was 
also detected in esophageal adenocarcinoma. In contrast, no CDX2 protein was 
observed in biopsies containing gastric type epithelium of the distal esophagus of 
patients with BE, nor in squamous epithelium of patients with reflux esophagitis 
without BE. Low levels of CDX2 mRNA were however detected in approximately 
one third of the squamous epithelium samples of patients with BE. The presence 
of CDX2 mRNA also correlated with goblet cell specific MUC2 mRNA in BE samples 
(Figure 3). 
  The homeobox protein CDX2 is involved in the differentiation and maintenance 
of intestinal epithelium [14]. Expression of CDX2 is detected at the time of mor-
phogenesis in the visceral endoderm of mouse intestine [28] and continues to 
be present throughout adulthood, but then is normally restricted to the intestine 
[29]. It is detectable in the crypts of the intestine as well as in the villi [15] and 
is suggested to be a key regulator of intestinal differentiation [19]. Exogenous 
expression of CDX2 in IEC6 cells, an undifferentiated rat intestinal cell line which 
Barrett's segment
6/19 CDX2
0/6 MUC2
6/6 MUC2
13/19 CDX2
3/13 MUC2
10/13 MUC2
Squamous epithelium
13/19 CDX2
0/13 MUC2
13/13 MUC2
6/19 CDX2
6/6 MUC2
0/6 MUC2
-
-
+
-
+
-
+
-
+
+
-
+
Figure 3   Schematic overview of the distal esophagus, summarizing the transcription of CDX2 mRNA and 
goblet cell-specific MUC2 mRNA in biopsies taken from the Barrett’s segment and the squamous epithe-
lium of patients with Barrett’s esophagus.
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does not express CDX2, causes differentiation of IEC6 cells into goblet cells and 
absorptive enterocytes [14]. Similar observations have been made in an animal 
model, in which ectopic expression of CDX2 induced the development of meta-
plastic changes of the gastric antrum, and in Helicobacter pylori-related intestinal 
metaplasia of the human stomach [30, 31]. These metaplastic changes of the 
mouse gastric antrum were also characterized by the development of goblet cells 
and absorptive enterocytes, and the expression of intestine specific proteins such 
as MUC2, alkaline phosphatase, villin, guanylyl cyclase C and trefoil factor 3 [21]. 
In contrast, heterozygous CDX2 knockout mice developed polyp-like lesions in 
their colon during the first 3 months of life, which lacked CDX2 expression [32]. 
These lesions were composed of heterotopic, well differentiated stratified squa-
mous epithelium, stomach and small intestinal mucosa [33]. It was concluded 
that CDX2 directs epithelial differentiation toward a caudal phenotype. For these 
reasons, CDX2 expression is believed to be an early marker of intestinal differen-
tiation and may therefore play a role in the development of SIE in the lower part 
of the esophagus, as observed in BE. 
  Although all additional biopsies taken from the BE-segment for histological eval-
uation in the group of patients in whom CDX2 mRNA was determined showed SIE, 
CDX2 mRNA was not detected in 6/19 (32%) BE segments. In the biopsies taken 
from these segments, MUC2 transcription was absent, which suggests that goblet 
cells were not present in these samples. As goblet cells are a hallmark of BE, these 
biopsies may have contained another type of columnar epithelium, probably gas-
tric type epithelium as was detected in 26/79 (33%) biopsies of the BE segment 
in this study. This is in agreement with findings in another study, which reported 
that goblet cells were only found in 51% of patients with 3-4 cm columnar-like 
epithelium of the esophagus on a first endoscopy [34]. This increased to 88.9% 
after 3 endoscopies [34]. This suggests that the absence of SIE in the biopsies 
taken from the columnar lined segment might be due to sampling error. Since in 
this study, only 1 of the 6 patients negative for CDX2 mRNA had an esophageal 
adenocarcinoma and no dysplasia was observed in the adjacent biopsies taken 
for routine screening in the other 5 patients, it is unlikely that a neoplasia, which 
is associated with a decreased number of goblet cells, was present in these biop-
sies. 
  In order to assess whether CDX2 is an early marker for the metaplastic replace-
ment in the esophagus, CDX2 mRNA levels were also determined in reflux-ex-
posed squamous epithelium of patients with BE. Low levels of CDX2 mRNA were 
indeed observed in 6/19 (32%) of the squamous epithelium samples tested (Fig-
ure 3). In addition, transcription of MUC2 was not detected in any of these sam-
ples, which excludes the possibility that SIE was covered by a stratified epithelial 
layer. This indicates that healthy appearing squamous epithelium 5 cm above the 
squamo-columnar junction of the esophagus in a subset of patients with colum-
nar metaplasia of the distal esophagus may already have undergone molecular 
changes, which may make them prone to the development of SIE, although this 
needs to be determined in a longitudinal follow-up study of patients with reflux 
esophagitis without BE. Patient-to-patient variation in the extent of reflux, the 
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severity of inflammation, and the effect of the medication used, may well explain 
why not all squamous epithelium samples of patients with BE contained detectable 
amounts of CDX2 mRNA.
  The development of BE is associated with pathologic reflux of acid [35] and/or 
bile [36]. Taken together with recent reports that CDX2 expression can be induced 
in keratinocytes by prolonged exposure to acid [37], CDX2 transcription may be an 
early step in the metaplastic replacement of esophageal squamous epithelium by 
SIE. We hypothesize that inflammation in the esophagus caused by duodenogas-
tro-esophageal reflux induces CDX2 expression in a subset of patients. Pathways 
involved in de novo CDX2 expression in esophageal squamous epithelium may be 
important for the development of Barrett’s esophagus. Elucidating these pathways 
may result in a greater understanding why only a subset of GERD patients develop 
Barrett’s esophagus. 
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ABSTRACT
Background Patients who have undergone esophagectomy with gastric tube re-
construction often have complaints of gastroesophageal reflux. A subset of these 
patients will develop columnar epithelium in the remnant esophagus, which can 
be of the gastric or intestinal type (Barrett’s esophagus). 
Aim To determine whether gastric-type mucosa in the esophagus is a precursor 
stage of intestinal metaplasia. 
Patients and Methods The medical records of 613 patients having undergone 
esophagectomy were reviewed for the endoscopic presence of segments with 
columnar mucosa in the remnant esophagus. Of them, 45 patients underwent 
endoscopic follow-up. The presence of intestinal metaplasia was determined 
histologically by haematoxylin and eosin, alcian blue, and periodic acid-Schiff 
staining in archival biopsy samples. Intestinal characteristics were identified by 
immunohistochemical staining for CDX2, MUC2 and cytokeratins 7 and 20. CDX2 
transcription was assessed by RT-PCR.
Results Eighteen of 45 patients (40%) had histologically proven columnar epi-
thelium in the remnant esophagus, and were included in this study. Histological 
analysis revealed gastric-type mucosa in all samples. Eight samples with gastric-
type mucosa also had foci of intestinal metaplasia. CDX2 and MUC2 expression 
was observed in the regions with intestinal metaplasia, and in two patients, CDX2 
expression was observed in gastric-type glands at a distance of intestinal glands. 
CDX2 transcription was identified in two patients without intestinal metaplasia. 
Diffuse cytokeratin 7 and superficial cytokeratin 20 expression was identified in 
both gastric-type mucosa and intestinal metaplasia. 
Conclusion In the majority of patients, expression of CDX2 and MUC2 was only 
detectable in intestinal metaplasia, but CDX2 was also observed in four cases in 
gastric-type mucosa. This could indicate that part of the gastric-type mucosa and 
the intestinal metaplasia may share a common pathway, eventually leading to the 
development of specialized intestinal epithelium. 
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INTRODUCTION
Barrett’s esophagus (BE) is a chronic inflammatory condition in which the normal 
squamous epithelium of the lower oesophagus is replaced by specialized colum-
nar epithelium of the intestinal type. This condition is most likely caused by gas-
tro-esophageal reflux [1]. Patients with BE have an increased risk of developing 
esophageal adenocarcinoma. 
  One of the histologic characteristics of BE is the presence of goblet cells. In ad-
dition to intestinal metaplasia (IM), gastric-type mucosa (GM) is also frequently 
observed in the distal esophagus, but this type of epithelium is probably not as-
sociated with an increased risk of esophageal adenocarcinoma [2]. It has been 
hypothesized however that IM could evolve from this gastric-type epithelium [3].
  The presence of IM is associated with the expression of intestinal proteins, such 
as CDX2, MUC2, and a specific expression pattern of cytokeratins (CK), i.e. CK7 
and CK20 [4-6]. CDX2 is a transcription factor involved in intestinal differentiation 
[7, 8], and overexpression leads to the formation of IM in the stomach of mice [9]. 
Since low mRNA levels have been observed in the esophageal squamous epithe-
lium of patients with BE [10], CDX2 may be responsible for skewing esophageal 
epithelial differentiation towards an intestinal phenotype and thus have an impor-
tant role in intestinal metaplasia development. The exact pathogenetic pathway 
of the development of columnar epithelium and IM in the esophagus has not yet 
been identified. It is generally accepted that components of gastroesophageal re-
flux - mainly acid, bile and pancreatic juice - are the cause of this condition. The 
role of CDX2 in this process is still under investigation, but it has been observed 
that CDX2 is upregulated in response to acid in an in vitro model [11], which 
implicates that components of gastroesophageal reflux can induce intestinal dif-
ferentiation in the exposed epithelium.
  Patients who underwent esophagectomy with gastric tube reconstruction are 
prone to develop reflux in the remnant esophagus, as the previous protection by 
the lower esophageal sphincter is no longer present. Prospective studies have 
shown that 50-75% of these patients will develop a segment of columnar epithe-
lium in the remnant esophagus and that in 25% of these segments IM is present 
[12-14]. These patients after esophagectomy and gastric tube reconstruction are 
therefore a human in vivo model to study the development of BE, as the onset of 
esophageal damage and the progression to IM can be closely monitored. 
   The aim of this study was to determine whether GM and IM are different enti-
ties or consecutive stages of metaplastic progression. Therefore, we investigated 
if early intestinal differentiation, by means of intestinal marker expression, was 
present in GM. If present, this could indicate that GM is indeed a precursor lesion 
for IM in the esophagus.
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PATIENTS AND METHODS
Patients and material
The medical records of 613 patients who underwent esophagogastroscopy after 
esophagectomy with gastric tube reconstruction between 1994 and 2004 in our 
centre were examined. For resection all anastomoses between the remnant es-
ophagus and the gastric tube were created monolayer handmade with absorbable 
suture and situated in the neck. Fourty-five patients (7.3%) received endoscopic 
follow-up a half year or longer after esophageal resection. Eightteen of these pa-
tients (40%) were identified with histologically proven columnar epithelium in the 
remnant esophagus. At the time of endoscopy, which was conducted after a mean 
of 58.7 months, there were no signs of recurrent high-grade dysplasia, adenocar-
cinoma or squamous cell carcinoma. Furthermore, dysplasia or carcinoma was not 
present in these segments. Archival paraffin embedded biopsies were available for 
all eightteen patients. For five patients, follow-up archival biopsies were obtained. 
This means that a total of 23 biopsies was analyzed histologically. For three pa-
tients frozen biopsies were available for RNA analysis. 
Histology and immunohistochemistry
Ten subsequent sections from one sample were mounted on adhesive slides, 
dried overnight at 37°C, and deparaffinized with xylene. One of serially sectioned 
slides (4 µm) was stained with haematoxylin and eosin (H&E) and evaluated for 
the presence of GM and/or IM. Alcian Blue (AB) and periodic acid-Schiff (PAS) 
staining in consecutive slides was performed to facilitate the detection of mucin-
producing goblet cells. All slides were evaluated by a specialized GI pathologist 
who was blinded for the origin of the samples. For immunohistochemistry, antigen 
retrieval was performed by boiling the deparaffinized samples in a 10 mM monoc-
itric acid buffer (pH 6.0) in a microwave for 15 min, and slowly cooling down to 
room temperature (CDX2, MUC2, and cytokeratin 7) or by treating the slides 10 
minutes with 0.1% pronase and 10 minutes with cold TBS buffer (cytokeratin 20). 
The samples were incubated in TBS buffer containing 10% rabbit non-immune 
serum (DAKO, Glostrup, Denmark), and 10% normal human plasma (DAKO) for 
30 minutes. Primary antibodies used were anti-CDX2 (clone 392M, Biogenex, San 
Ramon, CA, USA) in a 1:100 dilution, anti-MUC2 (clone Ccp58, Novocastra, New-
castle upon Tyne, UK) in a 1:100 dilution, anti-cytokeratin 7 (clone ov-TL 12/30, 
Biogenex) in a 1:50 dilution, and anti-cytokeratin 20 (clone KS 20-8, DAKO) in a 
1:160 dilution. Detection was performed with a biotin-labeled rabbit anti-mouse 
antibody (DAKO), followed by the addition of a streptavidine-alkaline phosphatase 
complex (DAKO) using new fuchsine as substrate.
CDX2 RT-PCR
Total RNA was isolated using TRIzol-reagent (Invitrogen, Groningen, The 
Netherlands), and remaining chromosomal DNA was subsequently removed 
with the DNA-free RNA kit (Zymo, Orange, USA). Reverse transcription (RT)-
PCR was performed using intron-spanning primers for CDX2 5’-CCCAGCGGCCA-
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GCGGCGAAACCTGT / 5’-TATTTGTCTTTTGTCCTGGTTTTCA and housekeeping gene 
β-actin -5’-CAAGGCCAACCGCGAGAAG / 5’-CAGGGTACATGGTGGTGCC. cDNA was 
synthesized with the use of avian myeloma virus reverse transcriptase (Promega, 
Madison, USA). Primers were annealed by cooling down from 70°C to room 
temperature, followed by cDNA synthesis through incubation for 30 min at 42°C. 
PCR-reactions (total volume of 25 µl) contained 1 μl of the cDNA solution, 1× PCR-
core buffer (Promega), 2 mM MgCl2, 0.4 µM forward and reverse primer, 200 µM of 
each nucleotide (Promega) and 0.02 U/µl GoTaq Taq polymerase (Promega). PCR 
conditions were 35 cycles at 94°C (30 s); 55°C (30 s) and 72°C (1 min). Southern 
blotting confirmed the identity of the CDX2 PCR products. 
RESULTS
Histological analysis for columnar epithelium
To identify regions with GM and IM, subsequent H&E, AB, and PAS stained slides 
were evaluated. GM was observed in all biopsy samples. Focal IM as characterized 
by the presence of goblet cells, was observed within the regions of GM in eight 
samples of seven patients (Table 1). The indication for resection in the 18 patients 
with a newly developed segment of columnar epithelium was high-grade dysplasia 
within BE (n=4) esophageal adenocarcinoma within BE (n=6), adenocarcinoma of 
the gastro-esophageal junction without visible Barrett’s epithelium (n=4), squa-
mous cell carcinoma (n=3), and congenital atresia (n=1). Incidence rates of GM 
and IM were not significantly different between these groups.
Table 1. Patient characteristics
Indication 
for resec-
tion *
n columnar 
epithelium
available 
biopsies
biopsies 
with GM
biopsies 
with IM**
Mean time 
after 
resection 
(months)***
BE + HGD 20 4 (20%) 5 5/5 1/5 50.0 (10-81)
BE + EADC 139 6 (4%) 7 7/7 2/7 38.2 (6-118)
EADC 223 4(2%) 4 4/4 2/4 80.5 (31-108)
SCC 184 3 (2%) 5 5/5 2/5 52.3 (11-132)
other 47 1 (1%) 2 2/2 1/2 148
total 613 18 (3%) 23 23/23 8/23 58.7 (6-148)
*Indication for resection: BE: Barrett’s esophagus, HGD: high-grade dysplasia, EADC: esophageal adeno-
carcinoma, SCC: squamous cell carcinoma, other: other indications, such as strictures or perforations
**IM was observed within regions of GM
***Mean interval between resection and the detection of columnar epithelium in the remnant esophagus 
after resection
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Intestinal marker expression
Expression of the intestinal proteins CDX2 and MUC2 was evaluated by immuno-
histochemistry. Nuclear CDX2 expression was observed in all 8 samples with IM. In 
6/8 biopsies, expression was only observed in regions with IM, but in two patients 
expression was also present both in IM and in GM at a distance of a region of IM 
(Figure 1a-b). These gastric glands were of the cardia-type. MUC2 expression was 
not detected in these latter glands. Both these patients underwent a resection for 
esophageal adenocarcinoma within Barrett’s esophagus. MUC2 expression was 
observed in the cytoplasm of goblet cells of all patients with IM (Figure 1c-d). Co-
localization of MUC2 expression and CDX2 expression was observed in all MUC2 
positive samples. 
Table 2. Immunohistochemistry results
protein GM IM
CDX2 2/23 8/8
MUC2 0/23 8/8
Cytokeratin 7 23/23 8/8
Cytokeratin 20 23/23 8/8
Figure 1   Histological and immunohistochemical detection of intestinal characteristics. A Nuclear CDX2 
expression in gastric-type glands at a distance of IM (arrow)(200x magnification). B The same region. 
Alcian Blue staining in adjacent gastric-type glands does not detect goblet cells (200x magnification). 
C cytoplasmic MUC2 staining in goblet cells (400x magnification). D Haematoxylin and Eosin staining 
in the same region (400x magnification). E Diffuse cytokeratin 7 staining in IM (100x magnification). F 
Superficial cytokeratin 20 staining in the same region (100 x magnification). A color version of this figure 
is printed on page 114.
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Figure 2   RT-PCR analysis of CDX2 and 
housekeeping gene β-actin transcripti-
on in three biopsies from the newly for-
med columnar segment of patients that 
underwent esophagectomy. Histological 
analysis of adjacent biopsy samples 
revealed IM in patient 2 and only GM 
in patient 1 and 3. Colon was used as a 
positive control. 
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Cytokeratin 7/20 pattern
Cytokeratin staining was evaluated as described by Ormsby et al [15]. A moderate 
to strong diffuse cytokeratin 7 cytoplasmic staining and strong superficial 
cytokeratin 20 cytoplasmic staining was considered as a “Barrett-like” staining 
pattern. This staining pattern was however observed in all samples, i.e. in GM as 
well as in IM (Figure 1e-f). 
CDX2 transcription
Frozen biopsy samples from three patients were available for RNA analysis. In 
the biopsy samples of all three patients, CDX2 mRNA was present, albeit in low 
amounts (Figure 2). Patient 2 had histologically proven IM, and patient 1 and 3 
only had GM. β-actin transcription was indicative for the amount of input RNA.
DISCUSSION
In the present study IM was observed in 7/18 patients who had developed a seg-
ment of columnar epithelium in the remnant esophagus after esophagectomy with 
gastric tube reconstruction. In all seven patients CDX2 expression was observed. 
CDX2 expression was also observed in gastric-type glands at a distance of IM (Fig-
ure 1a). Furthermore, CDX2 transcription was observed in two samples without 
IM (Figure 2). We therefore propose that the expression of CDX2 in gastric-type 
glands could be indicative of early intestinal differentiation in columnar epithelium 
and that GM is related to IM. In a few repeated prospective studies, the develop-
ment of IM from GM has been reported [14, 16].
  It is hypothesized that Barrett’s esophagus arises from a pluripotent stem cell, 
that is normally capable of both gastric and intestinal differentiation [17] as well 
as differentiation into squamous epithelium [18]. In the esophagus, these cells 
will normally differentiate into squamous epithelium, but under influence of reflux-
induced chronic inflammation this differentiation may be directed towards forma-
tion of columnar epithelium [19]. It could well be that these stem cells initially 
will differentiate into GM, but a stimulus such as acid or inflammatory mediators 
is able to induce the expression of CDX2 in this epithelium, which will also lead to 
the expression of other intestinal proteins, leading to an intestinal phenotype.
  MUC2 expression was only observed in goblet cells in IM, and not in the colum-
nar cells of GM. MUC2 is a CDX2-regulated mucin [20], but co-localization with 
CDX2 was only present in IM and not in adjacent GM. This indicates that despite 
its CDX2 regulation, MUC2 seems not to be involved in early differentiation. PAS 
staining was observed throughout the biopsy samples and this was only indicative 
for the presence of goblet cells. Alcian Blue staining was also observed in goblet 
cells and in some samples in other mucin producing columnar cells. However, it 
has been reported previously that these alcian blue positive columnar non-goblet 
cells are not indicative for the presence of intestinal differentiation [21]. 
  The cytokeratin pattern of GM and IM was also determined in this study. The 
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expression of cytokeratins 7 and 20 has been reported to provide a pattern that 
is unique for BE, and therefore could be able to distinguish BE from GM and from 
IM of the cardia [15, 22]. The present study, but also other studies [23], did not 
confirm this observation as similar cytokeratin 7/20 patterns were observed in 
both GM and IM.
  Until now there has been only a single study that has reported on the expression 
of markers in IM of the remnant esophagus, i.e. cyclooxygenase 2 and binding of 
the antibody DAS-1 [24]. The current study is the first to report for CDX2 expres-
sion in the newly formed IM in the remnant esophagus.
  It has been reported that 50-75% of patients who have undergone esophagecto-
my with gastric tube reconstruction will develop a segment of columnar epithelium 
in their esophageal remnant after a mean of 38-61 months after esophagectomy 
[12-14]. However, these studies were performed on selected patient groups. In 
retrospective studies with an unselected population, an incidence of 10% has been 
reported [24, 25]. Our frequency of columnar epithelium was 40% in patients that 
had endoscopic follow-up. We do not routinely perform follow-up upper GI endo-
scopies in patients who have undergone esophageal resection. In this study, only 
7.3% of esophagectomy patients underwent gastroscopy after resection, but less 
than half of the patients survived longer than two years after esophagectomy and 
thus only in a small selection of patients newly formed columnar epithelium can 
be detected. Patients who were diagnosed with newly formed columnar epithelium 
underwent upper GI endoscopy for other indications, mostly dilation of strictures 
or suspicion for recurrent carcinoma, which was however not present in any of 
these patients. 
  GM and IM were not only observed in patients who underwent esophageal 
resection for adenocarcinoma, but also in patients who had had squamous cell 
carcinoma. This is not new as others also reported this finding [12, 13, 24]. It 
does however indicate that BE is more likely an acquired, i.e. induced, than an 
inherited, i.e. preexistent, condition.
  In conclusion, CDX2 expression is present in IM, and in four patients, CDX2 was 
observed in GM at a distance of IM or without IM. This study was performed in 
a relatively small group of patients that developed a segment of columnar epi-
thelium in the remnant esophagus, but nevertheless, it provides evidence that 
GM and IM share a common pathway, eventually leading to the development an 
intestinal phenotype. 
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ABSTRACT
Barrett’s esophagus is defined as the presence of columnar epithelium with intes-
tinal metaplasia in the esophagus. However, non-metaplastic gastric-type muco-
sa, which can be of the fundic or cardia-type, is also frequently present in the es-
ophagus. The aim of this study was to investigate whether CDX2, an early marker 
for intestinal differentiation, was present in gastric-type mucosa in patients with 
endoscopic Barrett’s esophagus and to characterize the expression of CDX2 regu-
lated MUC2 in this epithelium. Biopsies taken from columnar epithelium of the dis-
tal esophagus were collected from 61 patients at two different endoscopies. Hae-
matoxylin and eosin, alcian blue and periodic acid-Schiff staining was performed 
to detect the presence of goblet cells, which are specific for intestinal metaplasia. 
CDX2 and MUC2 expression was determined by immunohistochemistry. Intestinal 
metaplasia was present in 55/122 samples. In all 55 samples with intestinal meta-
plasia CDX2 and MUC2 expression was detected. Furthermore, CDX2 expression 
was also observed in gastric-type glands adjacent to or at distance of intestinal 
metaplasia, which were all of the cardia-type. In addition, CDX2 was detected in 
cardia-type mucosa in 23/67 samples without intestinal metaplasia. In thirteen of 
these biopsies MUC2 positive goblet-like cells that were negative for alcian blue 
were detected. In conclusion, it was shown that in addition to intestinal meta-
plasia and cardia-type mucosa, a hybrid of these two epithelium types that has 
several intestinal characteristics but does not contain fully differentiated goblet 
cells is present. These results implicate that intestinal metaplasia and cardia-type 
mucosa in the esophagus are related to each other.
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INTRODUCTION
Barrett’s esophagus (BE) is a premalignant condition that is characterized by the 
replacement of the normal squamous epithelium of the esophagus by columnar 
epithelium of the intestinal type, intestinal metaplasia (IM). Gastroesophageal re-
flux is generally accepted as the major causative agent of BE [1]. BE can progress 
to esophageal adenocarcinoma via intermediate stages low-grade dysplasia and 
high-grade dysplasia [2].
  In addition to IM, gastric-type mucosa (GM) is also frequently observed in the 
columnar lined esophagus [3], however only IM is supposed to be associated with 
adenocarcinoma development [4]. GM can be subdivided in fundic-type mucosa 
and cardia-type mucosa (CM). The distribution of IM in the columnar segment is 
usually patchy, but it is mainly localized at the proximal end of the columnar seg-
ment [5]. Due to sampling error, IM can be missed and patients with only patchy 
IM could falsely be excluded from surveillance programs [6]. Several authors have 
suggested IM and GM are related to each other [7, 8], however, at present there 
is no biological evidence that supports this theory. 
  The homeobox protein CDX2 is a transcription factor involved in intestinal dif-
ferentiation [9]. It regulates transcription of several intestinal proteins, such as 
MUC2 and sucrase-isomaltase [10, 11]. CDX2 is involved in the development of 
IM, since CDX2 transgenic mice have developed IM in the gastric antrum [12]. 
CDX2 expression has also been observed in BE [13, 14], and CDX2 mRNA has 
been detected in the squamous epithelium of patients with BE [15]. This indicates 
that CDX2 is also involved in intestinal differentiation in Barrett’s esophagus. It 
has been reported that CDX2 is also present in GM outside regions with in the 
esophagus [13]. However it is not clear if this epithelium has other intestinal 
characteristics.
  The aim of this study is to determine if early intestinal differentiation in GM, by 
means of CDX2 expression, is present in a population of patients with endoscopic 
BE in which IM had not been observed at all endoscopies, and if present, to char-
acterize other phenotypic characteristics of this epithelium.
PATIENTS AND METHODS
Patients and material
Sixty-one patients that had had at least two follow-up endoscopies with biopsies 
were selected for this study. The biopsies were selected for i) the presence of IM 
in both biopsies, ii) the presence of IM in one biopsy sample and only GM in the 
other, and iii) the presence of only GM in both biopsies, based on the pathology 
reports. From all patients, archival paraffin embedded biopsy sets were available. 
Based on the presence of IM, the patients were divided into three groups (Table 
1): group I: patients with IM in biopsy sets from both endoscopies, group II: 
patients with IM in biopsy sets from one endoscopy, but with no IM in biopsy sets 
from the other endoscopy, and group III: patients with no IM in biopsy sets from 
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the first and the second endoscopy. This study was approved by the local ethical 
review board and informed consent was obtained prior to endoscopy.
Histology and immunohistochemistry
Four subsequent sections (4 µm) from one sample were mounted on adhesive 
slides, dried overnight at 37°C, and deparaffinized with xylene. One of these seri-
ally sectioned slides was stained with haematoxylin and eosin (H&E) to evaluate 
for the presence of GM or IM. Alcian Blue and periodic acid-Schiff (PAS) stainings 
in consecutive slides were performed to facilitate detection of mucin producing 
goblet cells. All slides were evaluated by a specialized GI pathologist. For immu-
nohistochemistry, antigen retrieval was performed by boiling the deparaffinized 
samples in a 10 mM monocitric acid buffer (pH 6.0) for 15 min, and slowly cool-
ing down to room temperature. Endogenous peroxidase activity was inhibited by 
using a 0.5% solution of H2O2 in phosphate-buffered citric acid for 15 minutes. 
The samples were incubated in TBS buffer containing 10% rabbit non-immune 
serum (DAKO, Glostrup, Denmark), and 10% normal human plasma (DAKO) for 
20 minutes. Sections were incubated for 16 hours at 4°C with primary antibody 
anti-CDX2 (clone 392M, Biogenex, San Ramon CA, USA) in a 1:100 dilution or 
anti-MUC2 (clone Ccp58, Novocastra, Newcastle upon Tyne, UK) in a 1:100 dilu-
tion. Detection was performed with a biotin-labeled rabbit-anti-mouse antibody 
(DAKO), followed by the addition of a streptavidin-horseradish peroxidase com-
plex (DAKO) using 3-amino-9-ethylcarbazole as substrate. Slides were analyzed 
for nuclear CDX2 and cytoplasmic MUC2 staining by two independent researchers 
that were blinded for presence of IM. Statistical analysis was performed using the 
chi-squared test using SPSS software (version 11.0 SPSS inc). A p-value < 0.05 
was considered significant. 
RESULTS
The presence of IM
IM was defined as the presence of goblet cell containing glands. Consecutive H&E, 
alcian blue, and PAS stained slides were evaluated for the presence of IM. In 17% 
of the biopsy sets there was disconcordance between the result of histological 
evaluation of these slides and the routine analysis performed at the biopsy set. In 
half of our samples IM was observed whereas the diagnosis of the routine patholo-
gist was negative and in the other half IM was not observed whereas the diagnosis 
of the routine pathologist was positive. An explanation for this disconcordance is 
probably the fact that the slides used in this study were cut from a region that was 
at least 0.1 mm deeper located in the paraffin blocks than the slides that were 
used for routine histology. In addition routine analysis was mostly performed by 
general pathologists, viewing only H&E stained slides, while we used additional 
alcian blue and PAS stained slides, and these were analyzed by a specialized pa-
thologist (HvD). The presence of IM based on the sections of this study was taken 
as starting point for further analyses for which consecutive slides were used.
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  In total, IM was observed in 55/122 biopsies (45%). 41/55 IM-positive biopsies 
contained both IM and GM and 14/55 IM positive biopsies contained only IM. 
Based on the presence of IM, group I (IM - IM) contained 15 patients, group II 
(IM - No IM) contained 25 patients, and group III (No IM - No IM) contained 21 
patients (Table 1). Mean age at first endoscopy, length of the columnar segment, 
interval between the two endoscopies, and use of proton-pump inhibitors were not 
statistically significant between these three groups.
Table 1. patient characteristics
I II III
1st endoscopy IM IM/No IM No IM
2nd endoscopy IM IM/No IM No IM
patients 15 25 21
mean age at first endoscopy * 58 (28-82) 55 (27-78) 54 (27-74)
mean length columnar segment (cm) * 3,87 (2-8) 3.37 (2-7) 2,56 (2-5)
interval between endoscopies (years) * 3 (0-13) 3 (1-9) 2 (0-10)
use of PPI* 18/23 15/20 10/18
*p=NS
CDX2 expression
CDX2 expression was defined as the presence of clear red coloration of at least 
four adjacent positive staining nuclei in the same gland. CDX2 expression was ob-
served in 100% of IM positive biopsies in group I (Figure 1a -b). In group II, all IM 
positive biopsies were also positive for CDX2 (Table 2). CDX2 expression was also 
observed in 23/67 biopsies without IM (Figure 1c-d), i.e. 13 in group II, and 10 in 
group III (Table 3). In 4/10 CDX2 positive samples of group III, IM had previously 
been observed in either one or both blocks during routine evaluation by a patho-
logist. However, in this study IM was observed in none of the two sets of biopsies. 
In one patient in group III, both IM negative biopsies were positive for CDX2.
  In samples with both IM and GM, CDX2 expression was not restricted to IM, but it 
was also observed in gastric-type glands that were located adjacent to the regions 
with IM (Figure 1e-f). In all cases, these gastric glands were of the cardia-type. 
Moreover, in some cases CDX2 expression was observed in cardia-type glands at 
a distance of the region with IM, on the other side of the biopsy sample (Figure 
1g-h). These results are shown in Table 3. Strikingly, CDX2 expression in adjacent 
cardia-type glands was observed more often in group II compared with group I 
(34% vs. 24%), while in group I expression was mainly restricted to IM regions 
compared with group II (63% vs 17%). These differences were not significant (p 
= 0.1), however, a trend was seen towards increased CDX2 expression outside 
regions with IM in the groups that had IM in only one set of biopsies.
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Table 2. CDX2 staining in all groups
I II III
biopsies 30 50 42
first endoscopy
IM 15 16 0
CDX2 * 15 24 5
MUC2 15 20 3
second endoscopy
IM 15 9 0
CDX2 * 15 14 5
MUC2 15 14 1
total
IM 30 25 0
CDX2 30 38 10
MUC2 30 34 4
*p<0.001
Table 3. Location of CDX2 and MUC2 staining
location I II III
CDX2
total CDX2 positive biopsies 30 38 10
only in IM part of biopsies 19 (63%)* 13 (34%) 0
in IM and in adjacent GM 5 (17%)* 9 (24%) 0
in IM and in GM at distance of IM 6 (20%) 3 (8%) 0
no IM present in biopsies 0 13 (34%) 10 (100%)
MUC2
total MUC2  positive biopsies 30 34 4
only in IM part of biopsies 23 (77%) 15 (44%) 0
in IM and in adjacent GM 6 (20%) 6 (18%) 0
in IM and in GM at distance of IM 1 (3%) 4 (12%) 0
no IM present in biopsies 0 9 (26%) 4 (100%)
*p=0.1
Figure 1   Immunohistochemical and histological analyses of CDX2 staining. a-b CDX2 and alcian blue 
staining in IM, 200 x magnification. c-d CDX2 and alcian blue staining of GM in samples without IM, 200 
x magnification. e-f CDX2 and alcian blue staining in gastric-type glands adjacent to IM, the region with 
IM is not visible in this picture, but located on the left sight of this picture. 200 x magnification. g-h CDX2 
and alcian blue staining in gastric-type glands at distance of IM, the region with IM is not visible in this 
picture, but is located on the other (left) site of this picture. 200 x magnification. A color version of this 
figure is printed on page 115.
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MUC2 expression
Cytoplasmic MUC2 staining in goblet cells was observed in all regions with IM. 
Staining of the extracellular mucus layer was not observed, since the antibody 
that was used only recognizes an epitope on the immature, not completely gly-
cosylated form of MUC2. Furthermore in most cases in which CDX2 was observed 
in adjacent and distant CM, MUC2 was also expressed in this regions (Table 3). 
Moreover, MUC2 was also expressed in CM in 13/67 samples without IM. In this 
epithelium, MUC2 was expressed in goblet-like cells, that however did not stain 
positive with alcian blue (Figure 2). 
A B
C D
Figure 2   Immunohistochemical and histological analyses of MUC2 staining. a-b MUC2 and alcian blue 
staining of GM in samples without IM. The same region as Figure 1c-d is shown. 200x magnification. c-
d Magnified view of MUC2-staining goblet-like cells in gastric-type glands.1000x magnification. A color 
version of this figure is printed on page 116.
DISCUSSION
Esophageal GM (CM or fundic-type epithelium) and IM often co-exist in the co-
lumnar-lined esophagus [3]. This study provides the first biological evidence that 
there is a intermediate type of epithelium is histologically similar to CM, but has 
CDX2 and in some cases MUC2 expression. Expression of the intestinal transcrip-
tion factor CDX2 was not only observed in IM, but also in adjacent and distant CM 
and even in CM in some samples without IM. 
  During embryonic intestinal development, low CDX2 levels are present in the ear-
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liest stages of intestinal formation [16]. These levels increase with the formation 
of intestinal columnar epithelium [9]. This indicates that CDX2 is an early marker 
for intestinal development. CDX2 expression in GM in the esophagus, as observed 
in this study, may represent early intestinal differentiation in this epithelium. 
  CDX2 could reveal early intestinal differentiation prior to morphologic changes, 
such as the presence of goblet cells, that are detected by conventional histological 
methods. Although possible due to the two-dimensional analysis of the biopsies, 
it is however unlikely that goblet cells have been missed in the analysis, as large 
areas without goblet cells, but with CDX2 expression were frequently observed 
(Figure 1g-h). This makes it highly unlikely that IM was present in these areas. 
  CDX2 expression in adjacent CM has been reported previously [17], however the 
present study focussed on this type of epithelium and determined further charac-
teristics. It was observed that in this some of these CM regions goblet-like cells 
were present that were positive for an immature form of MUC2, but did not stain 
with alcian blue. This suggest that the MUC2 apomucin is present, but that the 
proteins that regulate the glycosylation are not expressed in this epithelium. 
  It is thought that columnar epithelium in the esophagus arises from a pluripotent 
stem cell, that is normally capable of both gastric and intestinal differentiation 
[18] as well as differentiation into squamous epithelium [19]. In the esophagus 
these cells will normally differentiate into squamous epithelium, but under influ-
ence of reflux-induced chronic inflammation this differentiation can go towards 
fundic-type mucosa, CM or IM [20]. The results of this study implicate that the 
stem cells can also differentiate into a hybrid epithelium that resembles CM but 
has intestinal characteristics such as CDX2 expression and MUC2 positive goblet-
like cells.
  In most cases, the presence of this hybrid epithelium was associated with the 
presence of IM in the patient, either in the other biopsy set, at an other cross-sec-
tion of the biopsy set used for routine histology, or in earlier biopsies that were not 
included in this study. The distribution of IM in the columnar segment is usually 
patchy [5], and due to sampling error, focal intestinal metaplasia can be easily 
missed, even when the four-quadrant biopsy protocol [21] is used. The detection 
of hybrid epithelium, by means of CDX2 staining, can probably reduce sampling 
error, since it can identify patients that have IM at an other site of the columnar 
segment.
  Furthermore, sampling error can also occur when focal IM at only one side of 
a biopsy is missed when routine histology is based on one or two cross-sections 
of the biopsy sets. CDX2 expression was observed in four of the disconcordant 
biopsy sets with only GM in this study, but with IM at previous routine histology. 
This observation illustrates the value of CDX2 in the detection of intestinal dif-
ferentiation.
  In conclusion, it was shown that in addition to intestinal metaplasia and cardia-
type mucosa, a hybrid of these two epithelium types is present that has several 
intestinal characteristics but does not contain fully differentiated goblet cells. 
These results implicate that intestinal metaplasia and cardia-type mucosa in the 
esophagus are related to each other.
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ABSTRACT
Patients with Barrett’s esophagus are at an increased risk of esophageal adenocar-
cinoma. During the process of neoplastic progression, changes occur in mucosal 
mucin expression. Mucin expression may thus represent a marker for the detec-
tion of dysplasia. Mucins protect epithelium from damage by foreign bodies, but 
have also been implicated in regulatory processes like apoptosis. The objective of 
this study was to determine the expression pattern of mucins in neoplastic Bar-
rett’s epithelium and correlate it with the expression pattern of apoptosis-mark-
ers Bax and Bcl-2. A total of 37 patients with Barrett esophagus were included. 
Sixteen patients had Barrett esophagus without dysplasia (BE), six patients had 
Barrett esophagus with high-grade dysplasia (HGD), and fifteen had an infiltrating 
adenocarcinoma (EAC). Biopsies were obtained from the squamous epithelium, 
BE, and, when present, from foci of suspected HGD or EAC. MUC1, MUC2, MUC3, 
MUC4, MUC5AC, MUC5B, and MUC6 as well as Bax and Bcl-2 mRNA were deter-
mined by semi-quantitative RT-PCR. Protein levels of MUC2, MUC5AC and MUC6 
were determined by immunoblotting. The mucin pattern varied between different 
stages of neoplastic progression in Barrett’s epithelium. All mucins except MUC4 
had low mRNA levels in squamous epithelium, and were at least 4 times higher in 
BE and HGD (p < 0.001). Most mucin mRNA levels were less markedly increased 
in EAC. In HGD and EAC, MUC4 levels were significantly elevated compared to 
BE (p = 0.037). The Bax/Bcl-2 ratio was increased in HGD compared to BE (ratio 
1.71 versus 0.83, p = 0.04). Protein levels of MUC2, MUC5AC and MUC6 were 
correlated well with mRNA data. Mucin expression varies during the development 
of EAC in Barrett’s epithelium. In particular MUC4 could serve as a tumor marker 
in this process. In contrast to animal studies, upregulation of MUC4 in HGD is as-
sociated with increased apoptosis. This suggests that MUC4 plays a minor role in 
the regulation of apoptosis in BE.
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INTRODUCTION
Barrett’s esophagus (BE) is a premalignant condition in which the normal squa-
mous epithelium of the lower esophagus is replaced by specialized intestinal epi-
thelium. Gastroesophageal reflux is believed to play an important role in causing 
BE [1]. Adenocarcinoma (EAC) is thought to develop in BE in a stepwise manner 
via low-grade dysplasia and high-grade dysplasia (HGD) [2]. EAC has a poor prog-
nosis, as metastasis occur early and symptoms present lately in the course of the 
disease. Overall, 5-year survival is only 10-15% [3]. 
  Early detection of malignant progression is the key factor for improving the 
outcome of esophageal EAC. Current guidelines recommend endoscopic surveil-
lance to detect dysplasia and to diagnose carcinoma at an early treatable stage 
[4]. However, the efficacy of endoscopic surveillance is thwarted by several fac-
tors [5]. Sampling error is likely to occur in endoscopic random-biopsy sampling 
[6]. In addition, a correct pathological diagnosis of dysplasia is difficult and focal 
neoplastic changes can easily be missed in small biopsy samples. This is reflected 
by a considerable inter- and intraobserver variability among pathologists in the 
interpretation of epithelial changes in BE [7].  
  The use of molecular markers in addition to normal endoscopical and histologi-
cal evaluation could significantly enhance the detection of neoplasia in BE, both in 
vitro and in vivo. Particularly markers that indicate the presence of HGD could be 
helpful in the identification of patients at risk of malignant transformation.
  Mucins are large glycoproteins that are the main components of the gel-like mu-
cus-layer on the surface of the intestine. This layer serves to protect the mucosa 
from mechanical damage. Each type of mucosa has a unique pattern of mucin 
expression, and this pattern changes during neoplastic progression. Therefore, 
mucins are putative molecular markers for the development of adenocarcinoma in 
BE. Currently, more than 10 MUC genes have been reported, the best-character-
ized being MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC5B, and MUC6. Of these only 
MUC1 and MUC4 are expressed in the normal squamous lining of the esophagus 
[8], whereas BE predominantly expresses MUC2 and to a lesser extent MUC5AC 
and MUC6 [9-11]. 
  In addition to protection against mechanical damage, membrane-bound mucins 
MUC1 and MUC4 have also been described to be involved in oncogenic pathways. 
MUC1 has an ability to bind β-catenin, thereby altering its ability to bind E-cad-
herin which leads to a decreased cell-cell adhesion and uncontrolled proliferation 
[12, 13]. MUC4, a mucin that is upregulated in several tumor-types, acts as ligand 
for the receptor tyrosine kinase Erb-B2, thereby regulating the p27kip cell-cycle 
inhibitor [14]. MUC4 also inhibits apoptosis in a xenotransplanted melanoma in 
nude mice [15]. 
  The objective of this study was to evaluate the expression patterns of MUC1-4, 
MUC5AC, MUC5B, and MUC6 in high-grade dysplasia and adenocarcinomas in Bar-
rett’s esophagus and determine the association with the apoptosis markers Bax 
and Bcl-2. 
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METHODS
Patients
A total of 37 patients with BE were included. Sixteen patients had BE without 
dysplasia, six patients had BE with high-grade dysplasia, and fifteen had an in-
filtrating adenocarcinoma. Patients were evaluated by standard esophagoscopy 
and high magnification chromendoscopy. Biopsies were obtained from the squa-
mous epithelium, Barrett’s epithelium, and, when present, from foci of suspected 
high-grade dysplasia or adenocarcinoma. Two expert gastrointestinal pathologists 
independently evaluated haematoxylin and eosin stained sections for the pres-
ence of BE, grade of dysplasia or EAC. Al patients with HGD were treated with 
endomucosal resection (EMR). Resected tissue was investigated histologically, and 
in none of 6 patients, invasive adenocarcinoma was found. Ten patients with ad-
enocarcinoma were treated surgically and 5 patients received palliative treatment. 
All adenocarcinomas had infiltrated into the submucosa and 3 patients had local 
lymph node metastases. Eight tumors were well and 7 were poorly differentiated. 
This study was approved by the ethical committee of the Erasmus MC Rotterdam 
and informed consent was obtained prior to endoscopy.
RNA and protein isolation from biopsies
Biopsies were snap-frozen in liquid nitrogen. Total RNA was isolated using Trizol-
reagent (Invitrogen, Groningen, The Netherlands) according to instructions of 
the manufacturer. Remaining chromosomal DNA was removed with the RNA-free 
DNA kit (Zymo, Orange, USA). Total RNA concentrations were estimated by RNA 
electrophoresis on an agarose gel and band intensity was compared with that of 
a marker band with a known concentration. From the same biopsy specimen, a 
protein fraction was isolated according to the instructions of the manufacturer and 
denatured in 1% sodium dodecyl sulphate. Protein concentrations were deter-
mined with the BCA protein assay kit (Pierce, Rockford, USA).
RT-PCR
cDNA was synthesized with the use of Avian Myeloma Virus reverse transcriptase 
(Promega, Madison, USA). Primers were annealed by cooling down from 70˚C to 
room temperature. cDNA was synthesized by incubation of the mRNA for 30 min 
at 42°C. PCR-reactions (total volume of 25 μl) contained 1 μl of the cDNA solution, 
1 x PCR-core buffer (Promega), 2 mM magnesium chloride, 0.4 µM forward and 
reverse primer, 200 µM of each nucleotide (Promega) and 0.02 U/μl Taq polymer-
ase (Promega). PCR conditions were 35 cycles at 94°C (30 s); 55°C (30 s) and 
72°C (1 min). PCR-products were visualized on a 1% agarose gel and stained with 
ethidiumbromide. Band size and intensity were measured with Kodak 1D software 
(Kodak, Rochester, USA) version 3.5 by normalizing against the housekeeping 
gene β-actin, as described previously [16]. All primers are listed in Table 1. 
Protein Cross-blot
Twenty microgram protein was loaded in the lanes of a reverse line blotter (Immu-
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netics, Cambridge, UK) on a PVDS membrane (Roche, Mannheim, Germany). Af-
ter one hour of incubation at room temperature the membrane was blocked in 5% 
Protifar non-fat milk (Nutricia, Cuijk, Netherlands) in phosphate buffered saline 
containing 0.1% Tween. The primary antibodies anti-MUC2 clone Ccp58 (Novo-
castra, Newcastle, USA), anti-MUC5AC clone 45M1 (Zymed, San Francisco, USA), 
and anti-MUC6 clone CLH5 (Novocastra) were loaded in an angle of 90 degrees 
on the protein samples. An alkaline phosphatase labelled Goat anti-mouse IgG 
antibody (Southern Biotech Associates, Birmingham, USA) was used as conjugate 
and 0.18 mg/ml 5-bromo-4-dichloro-3-indolyl phosphate (BCIP, Promega) and 
0.35 mg/ml Nitroblue Tetrazolium (NBT, Promega) in 0.1M Tris-HCl pH 9.5, 0.1M 
NaCl, and 5 mM MgCl2) were added as substrate. Immunohistochemical stain-
ing of gastric antrum and colonic mucosa confirmed that the primary antibodies 
detected the mature mucin protein in case of MUC5AC and MUC6, or a precursor 
peptide, in case of MUC2.  
Statistical analyses
RT-PCR data are presented as mean ± SEM. Statistical analyses were performed 
with the Mann-Whitney U-test. A p-value <0.05 was considered statistically sig-
nificant. 
RESULTS
Mucin mRNA levels
The results of RT-PCR testing of different mucins in squamous epithelium, BE, 
HGD, and EAC are shown in Figure 1. The mean transcription levels of individual 
mucins relative to transcription of β-actin in the same sample are given in Figure 
2. Overall, mucin transcription levels were low or absent in squamous epithe-
Table 1. PCR-Primers
Amplified 
gene
Forward primer Reverse Primer
MUC1 5’TGCATCAGGCTCAGCTTCTA3’ 5’ACGTCGTGGACATTGATGGT3’
MUC2 5’CAGGATGGCGCCTTCTGCTA3’ 5’ÁTGCTGCTCCAAGCTGAGGT3’
MUC3 5’CCAGCCAGGATGTGAACAG3’ 5’GACAGTCGATGGCGTTGTC3’
MUC4 5’TCAACGCCTCGGTGGCATAC3’ 5’CTGTCACATCGCGCACGTCT3’
MUC5B 5’TTGACGGCACCTCTTACACC3’ 5’GCCTGGAAGACTTGGCCATT3’
MUC5AC 5’CCGGAGGTGAACATTGAAC 3’ 5’TCTGTGGCGGTATATGGTG3’
MUC6 5’GCAGGAGGAGATCACGTTCA3’ 5’CGCCTCCTCTGTGGCTTCAT3’
Bax 5’GGCCCACCAGCTCTGAGCAGA3’ 5’GCCACGTGGGCGTCCCAAAGT3’
Bcl-2 5’GTGGAGGAGCTCTTCAGGGA3’ 5’ÁGGCACCCAGGGTGATGCAA3’
β-actin 5’GACAGGATGCAGAAGGAGAT3’ 5’AGTCATAGTCCGCCTAGAAG3’
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MUC1
MUC2
MUC3
MUC4
MUC5AC
MUC5B
MUC6
-actin
S
q
B
E
H
G
D
EA
C Figure 1   Representative examples of RT-PCR results. mRNA of MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC5B and 
MUC6 in squamous epithelium (Sq), Barrett’s esophagus 
(BE), High-grade dysplasia (HGD), and adenocarcinoma 
(EAC). mRNA was isolated from biopsy samples of a patient 
with BE containing HGD and EAC. β-actin was used as control 
for RNA-input. PCR products were analyzed on a 1% agarose 
gel containing ethidiumbromide. 
lium (relative transcription level < 0.2), except for MUC4 (relative transcription 
level 1.1). Compared with squamous epithelium, MUC4 was downregulated in 
BE (relative transcription level 0.62; p = 0.01), while other tested mucins were 
considerably upregulated in BE (relative transcription level > 0.4, p<0.001). In 
HGD, transcription levels of mucins resembled that of BE, except for MUC4, which 
was significantly higher in HGD than in BE (relative transcription levels 1.27 ver-
sus 0.62; p = 0.037). In most adenocarcinomas, mucin mRNA levels were lower 
compared to BE without dysplasia or with HGD. Amplification of residual chromo-
somal DNA was not found. Sequencing and comparison with previous published 
sequences confirmed the authenticity of the mucin PCR-products. 
Mucin protein expression 
Protein fractions from the same biopsies as the mRNA fractions were analyzed by 
protein cross-blot to determine the mucin patterns on a protein level (Figure 3). 
Commercial antibodies that recognize the denatured antigen were only available 
for MUC2, MUC5AC and MUC6. Cross-blot analysis revealed that in squamous 
epithelium expression was present for MUC2 in 2/32 patients, for MUC5AC in 
9/32 patients, and MUC6 in 2/32 patients. In more than half of the BE samples, 
expression of MUC2 (17/30 patients), MUC5AC (28/30 patients), and MUC6 (26/
30 patients) was found. In HGD, MUC6 was expressed in 15/30 samples, while 
expression of MUC2 and MUC5AC was comparable to that in BE (3/6 and 6/6 re-
spectively). MUC5AC and MUC6 protein were found in 9/15 and MUC2 protein in 
3/15 of the EAC samples (Figure 4). Protein data were found to correlate with the 
mRNA data. 
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Figure 2   Mean relative expression levels of MUC1 (a), 
MUC2 (b), MUC3 (c), MUC4 (d), MUC5AC (e), MUC5B 
(f) and MUC6 (g). Quantitation of mucin mRNA levels 
was performed by normalizing the band-area and in-
tensity with that of β-actin. Sq = squamous epithelium 
(n=32), BE = Barrett’s esophagus (n = 30), HGD = 
high-grade dysplasia (n = 6) and EAC = adenocarci-
noma (n = 15)
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Bax and Bcl-2 mRNA levels in correlation with mucin mRNA levels
The correlation between mucin mRNA levels and the apoptosis-markers Bax and 
Bcl-2 was determined by calculating the ratio between mRNA-levels of the pro-
apoptotic Bax and the anti-apoptotic Bcl-2. mRNA levels of Bax and Bcl-2 were 
determined by semi-quantitative RT-PCR. The results are shown in Figure 5. The 
Bax/Bcl-2 ratio was increased in HGD compared to BE (ratio 1.71 versus 0.83, p 
= 0.04). In EAC, the ratio was lower than in HGD (0.95), but this difference was 
not statistically significant (p > 0.22). The elevated Bax/Bcl-2 ratio in HGD was 
associated with an increase in MUC4 mRNA.
b s b s b s h b s b a a h b
MUC2
MUC5AC
MUC6
Figure 3   Representative example of protein 
cross-blot. Protein samples were spotted in la-
nes on a membrane. Primary antibodies were 
spotted in lanes in an angle of 90˚ and were 
detected with an alkaline phophatase labelled 
secondary antibody. s = squamous epithelium, 
b = Barrett’s esophagus, h = high-grade dys-
plasia, a = adenocarcinoma
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Figure 4   Protein cross-blot analysis: percentage of samples 
positive for MUC2 (a), MUC5AC (b) and MUC6 (c). Sq = squa-
mous epithelium (n=32), BE = Barrett’s esophagus (n = 30), 
HGD = high-grade dysplasia (n = 6) and EAC = adenocarcinoma 
(n = 15)
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DISCUSSION
Changes in the expression pattern of mucins have been associated with the de-
velopment of early carcinomas of the colon, gallbladder and the respiratory tract 
[17-20]. The expression pattern of mucins in esophageal adenocarcinoma has 
also been determined [9, 10, 21], however the mucin pattern in high-grade dys-
plasia, the lesion that is preceding infiltrating adenocarcinoma, has not been clari-
fied. In this study, the transcription and expression of various mucins in biopsies 
of esophageal squamous epithelium, BE, HGD and EAC were determined. From 
each biopsy sample, both RNA and protein were purified, thus minimizing sample 
discordance between RNA and protein analysis. Most mucins were upregulated in 
BE compared to squamous epithelium. In adenocarcinomas, a greater variety with 
a trend towards lower mucin expression compared to BE was seen. Compared to 
non-dysplastic BE, HGD contained higher levels of MUC4 mRNA. 
  High expression of the secreted mucins MUC2, MUC5AC, MUC5B and MUC6 has 
previously been reported in BE [9, 21], as is their downregulation in esophageal 
adenocarcinoma of the esophagus [9, 10]. In contrast to these reports, low levels 
of these mucins were found in some squamous epithelium samples. Since RT-
PCR is a very sensitive technique, these low levels could have escaped detection 
in immunohistochemical studies. Also the possibility that the squamous samples 
are contaminated with some intestinal glands or subepithelial proper glands can 
not be excluded. Adjacent biopsies were analyzed for purity of epithelium, since 
approaches designed for extraction of mRNA from fixated tissue that is used for 
histological analysis, are not validated for the quantitative comparison of mRNA-
levels. Furthermore, the presence of MUC2, MUC5AC and MUC6 protein in the 
squamous epithelium could have been caused by reflux of gastric mucus compo-
nents, including these mucins.
  Most reports describe also high expression of MUC1 in squamous epithelium and 
low expression in BE [9, 10, 22], whereas the opposite is shown in the present 
study. An explanation for this could be that most studies used independent sq-
uamous epithelium samples, whereas in this study paired squamous/BE samples 
Sq BE HGD EAC
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Figure 5   Summary of data of Bax/Bcl-2 ratios. Quan-
titation of Bax and Bcl-2 mRNA levels was performed by 
dividing the band-area and intensity of Bax by that of 
Bcl-2. Sq = squamous epithelium (n=9), BE = Barrett’s 
esophagus (n = 8), HGD = high-grade dysplasia (n = 6) 
and EAC = adenocarcinoma (n = 4)
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from a single patient were used in which inflammation could have been altered the 
mucin pattern. The most striking result however is the upregulation of MUC4 in 
HGD compared to BE without dysplasia. This has not been reported before.
  Duodenogastro-esophageal reflux has been implicated in the development of 
Barrett’s esophagus and esophageal adenocarcinoma [23]. Recently it was found 
that in particular bile salts and their conjugates induce the transcription of MUC4 
mRNA in esophageal cancer cells [24]. This could explain the observed increase 
of MUC4 in HGD. 
  Increased MUC4 expression has also been found in other early neoplastic lesions 
like early pancreatic carcinomas and dysplastic cervical lesions [25, 26]. When 
produced in normal quantities, MUC4 has been described to function as a steric 
barrier that limits the access of other cells and large molecules to the epithelium, 
thereby protecting it from damage [27]. On the other hand, overexpression of 
MUC4 disrupts the cell-cell and cell-matrix interactions, which could initiate the 
dissociation of tumor cells from the primary tumor [28]. Finally, overexpression of 
MUC4 may result in the masking of tumor antigens, thereby effectively suppress-
ing tumor cell killing by cytotoxic lymphocytes [27]. Since esophageal adenocar-
cinoma often metastasizes in an early phase, loss of cell adhesion probably occurs 
already in an early stage of carcinogenesis. Increased MUC4 expression could at-
tribute to the detachment of tumor cells from the primary adenocarcinoma. 
  MUC4 protein also acts as ligand for the receptor tyrosine-kinase Erb-B2, a pro-
to-oncogene that is abnormally expressed in membranes of Barrett’s epithelium 
and associated adenocarcinoma [29, 30]. The MUC4-Erb-B2 complex is involved 
in the inhibition of apoptosis [31], thereby promoting tumor growth. A strong 
suppression of apoptosis was observed in MUC4 overexpressing tumors in mice 
[15]. In this study, the mRNA levels of apoptosis markers Bax and Bcl-2 were 
also determined. Inhibition of apoptosis was not found in the HGD samples with 
increased MUC4 expression. In contrast, the Bax/Bcl-2 ratio was increased in HGD 
compared to BE. This might indicate that MUC4 has only a minor role in regulation 
of apoptosis in HGD in humans. 
  An increased apoptotic rate does not fit in the model of neoplastic progression 
[32]. However, reduced Bcl-2 expression during neoplastic progression of Bar-
rett’s esophagus has been reported before [33]. A recent report described clear 
Bax and Bcl-2 expression in both BE, HGD and EAC, but results were not quantita-
tive [34]. Other apoptotic proteins, like Fas-ligand and caspases may be involved 
in an anti-apoptotic effect in BE with HGD, as compensation for the pro-apoptotic 
Bax/Bcl-2 balance. 
  The results of this study show that mucin expression is elevated in Barrett’s 
esophagus. Membrane-bound mucin MUC4 is associated with the development of 
high-grade dysplasia in Barrett’s esophagus, but not with a decrease in apoptosis. 
This suggests a role for MUC4 as early tumor marker in Barrett’s esophagus. In 
combination with other tumor markers it could facilitate the diagnosis of an early 
adenocarcinoma both in vitro and in vivo. However, additional studies are neces-
sary to verify this observation. 
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High-grade dysplasia in Barrett’s esophagus 
is associated with increased expression of cal-
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ABSTRACT
Background Patients with Barrett’s esophagus are at increased risk of developing 
esophageal adenocarcinoma, a type of carcinoma that is preceded by dysplastic 
changes of the metaplastic mucosa. The aim of this study was to identify genes in-
volved in the development of high-grade dysplasia in order to increase our under-
standing of the development of early neoplastic lesions in Barrett’s esophagus. 
Methods Seventy-six biopsies from 42 patients were included. Paired biopsy 
samples from non-dysplastic Barrett’s esophagus and high-grade dysplasia from 
a single patient were split and used for histological evaluation and transcription 
profile analysis. Relative mRNA levels were tested for association with presence or 
absence of dysplasia. The other biopsy samples, including squamous epithelium, 
Barrett’s esophagus, high-grade dysplasia and adenocarcinoma were used for 
testing the transcription profile by semi-quantitative RT-PCR and immunohisto-
chemistry. 
Results In high-grade dysplasia, 866 genes showed a >2-fold difference in mRNA 
levels compared to Barrett’s esophagus. Of these, 33 displayed a >10-fold differ-
ence. Determination of mRNA levels by RT-PCR for 22 of these genes revealed two 
significantly upregulated genes in high-grade dysplasia, calgranulin A (S100A8; 
p = 0.017) and calgranulin B (S100A9; p = 0.022). Levels of calgranulin A and B 
protein were also increased in high-grade dysplasia. For the other 20 genes, dif-
ferences in mRNA levels between high-grade dysplasia and Barrett’s esophagus 
were observed, but none of these was significant. 
Conclusion Calgranulin A and B are subunits of the calprotectin (S100A8/A9) 
complex that is involved in chemotaxis of neutrophils. This study reports for the 
first time that calprotectin may play a role in the development of neoplasia in 
Barrett’s esophagus. In addition, this study shows that differentially expressed 
proteins in biopsies from Barrett’s esophagus may be part of an array-like diag-
nostic test, that could facilitate the detection and diagnosis of advanced dysplasia 
in Barrett’s esophagus.
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INTRODUCTION
Barrett’s esophagus is a premalignant lesion, which is associated with gastro-es-
ophageal reflux [1]. Patients with Barrett’s esophagus have an increased risk for 
the development of esophageal adenocarcinoma [2]. Adenocarcinoma is thought 
to develop in Barrett’s esophagus in a stepwise manner via low-grade dysplasia 
(LGD) and high-grade dysplasia (HGD) [3].To date, the cellular and molecular 
mechanisms leading to neoplastic progression in Barrett’s epithelium are still only 
partially understood [4]. 
  HGD is generally seen as a precursor lesion for esophageal cancer, as a group 
of patients with HGD progresses to adenocarcinoma [5]. Several processes have 
been implicated in the transition of Barrett’s metaplasia to HGD. For example, ac-
cumulation of p53 protein in HGD impairs apoptosis, reduced E-cadherin expres-
sion disturbs the cell-cell adhesion, and increased MUC4 expression induces tumor 
growth [6-8]. As none of these factors occurs in all HGD lesions, they do not seem 
to play a key role in the development of HGD, and other genes involved in this 
process still have to be identified. Several approaches to identify genes involved in 
neoplastic progression, such as immunohistochemical detection of known genes in 
tumor tissue, have been used, but these are restricted to genes that have already 
been implicated in cancer development. 
  Techniques like gene transcription profiling may aid in the identification of genes 
involved in neoplastic progression [9]. The biological processes underlying tum-
origenesis will allow for improved detection and treatment of early neoplasms. In 
this study, an mRNA-based approach was used to identify genes whose transcrip-
tion is affected by the transition from Barrett’s esophagus without dysplasia to 
Barrett’s esophagus with HGD. As the aim of this study was to identify major tran-
scriptional changes in the esophageal tissue, it was decided to obtain RNA from 
complete routine clinical biopsy materials rather than using a method like laser 
capture microdissection to analyze these changes in a small group of specific cells. 
As a global gene profiling approach still requires significant amounts of RNA, we 
performed gene transcription profiling on material obtained from different loca-
tions of the esophagus from a single patient. Obtaining RNA from the various clini-
cal stages of esophageal disease of a single, well characterized patient eliminates 
false positive results from interpatient differences. To test the general validity of 
the genes differentially transcribed, a semi-quantitative RT-PCR was performed on 
paired samples of a large panel of patients.
MATERIALS AND METHODS
Patients
A total of 76 biopsies from 42 patients with Barrett’s esophagus without dyspla-
sia (BE), high-grade dysplasia (HGD) or adenocarcinoma (EAC) were included 
(Table 1).  Patients were evaluated by standard esophagoscopy and high mag-
nification chromendoscopy. For microarray, jumbo biopsies were obtained from 
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BE and HGD, and for semi-quantitative RT-PCR, biopsies were obtained from the 
squamous epithelium (Sq), BE, and, when present, from foci of suspected HGD, 
or adenocarcinoma. Eighty percent of the samples were paired. Adjacent biopsies 
were used for histology. Archival biopsies were obtained for the immunohisto-
chemical analysis. All biopsies were analyzed by two expert pathologists, who in-
dependently evaluated haematoxylin and eosin-stained sections for the presence 
of intestinal metaplasia, grade of dysplasia, or EAC. This study was approved by 
the institutional review board of the Erasmus MC Rotterdam and informed consent 
was obtained from patients prior to endoscopy.
Microarray based transcriptional profiling
Total RNA was isolated from BE and HGD biopsy specimens with the nucleobond 
RNA kit (BD Clontech, Palo Alto, CA) according to the instructions of the manuc-
facturer. cDNA was synthesized and labeled using the Atlas Pure Total RNA labeling 
system (BD Clontech) according to the instructions of the manufacturer. cDNA was 
hybridized with the BD Atlas plastic human 12K array (BD Clontech) consisting of 
a chip with 11835 genes, including positive controls such as β-actin, GAPDH, and 
α-tubulin as well as negative controls and controls for cDNA synthesis. Microarray 
data were analyzed using Atlasimage 2.7 software (BD Clontech).
Table 1. Patient characteristics
patientgroups patients Mean age
(range)
% male Biopsies obtained
Sqd BE HGD EAC
Microarray
HGDa 1 53 100 0 1 1 0
Total 1 0 1 1 0
RT-PCR
BEb 13 63.8 (33-85) 46 12 13 0 0
HGD 2 62.5 (53-72) 50 2 2 2 0
EACc 8 70.6 (57-81) 63 7 7 3 8
Total 23 21 22 5 8
IHCe
BE 9 57.3 (36-85) 78 0 9 0 0
HGD 9 68.1 (53-79) 89 0 0 9 0
Total 18 0 9 9 0
a HGD: Barrett’s esophagus with high-grade dysplasia
b BE: Non-dysplastic Barrett’s esophagus
c EAC: Esophageal adenocarcinoma
d Sq: Esophageal squamous epithelium
e IHC: Immunohistochemistry
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Table 2. Primers used for RT-PCR analysis
Gene products Forward primer 5’…3’ Reverse primer 5’…3’ Ta Sizeb
Aldolase B agcagaagaaggagctctca agcacctccttggtctaact 55 311
CA11 gctggacttcttggagtctt cttgctcaggtcatcgactt 50 378
Calgranulin A cgtctaccacaagtactc ccagtaactcagctactc 50 253
Calgranulin B tggaacgcaacatagagacc atgaactcctcgaagctcag 50 217
Cytokeratin 4 cctggacctggacagcatta gccacggatacctgaagagt 53 249
Cytokeratin 13 ccgtggtgtctctacctgtt ccagcctggcattgtcaatc 53 479
Fatty acid binding protein 1 gctctattgcaccatgagt ttgtctccagctcacattcc 50 243
Fatty acid binding protein 2 ttggaaggtagaccggagtg gttcagttccgtctgctagg 47 218
Gastric lipase caacagccttgccttcattc gcaacaggagctagagcata 50 309
H+K+ ATPase gtgtggatcagcctgtacta gaacttgcaggagaacttgg 50 351
Hydroxysteroiddehydrogenase aacctggaggcttcctaaca gcaaggcagatccacaagta 50 271
Integral membrane protein 2B aagaagagcctggtgttg ggacaggcacactgataa 47 257
Junction plakoglobin cgtgtgctcaaggtgctatc gtgtcaccagcgtcttgttc 53 295
MUC5B ttgacggcacctcttacacc gcctggaagacttggccatt 55 361
Pepsinogen A gaacctggctccttcctgta gatgtcgctctggatgttgg 53 387
Pepsinogen C tcggcttgagtgagaatgag atgccaatctgccagtagag 53 283
Prostate stem cell antigen aagcccaggtgagcaacgagga tggcgttgcacaagtcggtgtc 53 204
Psoriasin gctgagaggtccataatagg tagtctgtggctatgtctcc 47 242
Ribosomal protein P1 gtgacagtcacggaggataa tcatcagactcctcggattc 50 257
TFF1 aatggccaccatggagaa ggacgtcgatggtattagga 53 230
TFF2 aactgcggcttccctggaat agaagcaccagggcacttca 53 238
Transthyretin ctgccttgctggactggtat atgcagctctccagactcac 50 202
β-actin gacaggatgcagaaggagat agtcatagtccgcctagaag 57 587
a Temperature used for annealing of primers
b PCR product length
Semi-quantitative RT-PCR
Total RNA was isolated from Sq, BE, HGD and EAC biopsies using Trizol-reagent 
(Invitrogen, Paisley, UK) and remaining traces of chromosomal DNA were elimi-
nated using the DNA-free RNA kit (Zymo, Orange, CA). cDNA was synthesized 
with the use of Avian Myeloma Virus reverse transcriptase (Promega, Madison, 
WI). Primers were annealed by cooling down from 70°C to room temperature. 
cDNA was synthesized by incubation of the mRNA for 30 min at 42°C. PCR-reac-
tions (total volume of 25 μl) contained 1 μl of the cDNA solution, 1x PCR-core 
buffer (Promega), 2 mM magnesium chloride, 0.4 µM forward and reverse primer, 
200 µM of each nucleotide (Promega) and 0.02 U/μl Taq polymerase (Promega). 
All primers were designed with aid of primer designer software (version 5.10, 
scientific and educational software) and are listed in Table 2. PCR conditions were 
35 cycles at 94°C (30 s) for denaturing; 47-57°C (30 s) for annealing, dependent 
on the primer couple used, and 72°C (1 min) for extention. PCR-products were 
visualized on a 2% agarose gel and stained with ethidiumbromide. PCR product 
identity was confirmed by sequencing. Band size and intensity were measured by 
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densitometry with Kodak 1D version 3.5 software (Kodak, New Haven, CT) by nor-
malizing against the housekeeping gene β-actin, as described previously [8]. RT-
PCR densitometric data are presented as mean +/- standard error of the mean. 
Statistical analyses were performed using the Mann-Whitney U-test. A p-value < 
0.05 was considered statistically significant.
Immunohistochemistry
Paraffin-embedded biopsy samples were serially sectioned at 4 µm, 15-20 sec-
tions from one sample, mounted on adhesive slides, dried overnight at 37°C, and 
deparaffinized with xylene. First and last sections of each series were stained with 
haematoxylin and eosin, and evaluated for the presence of intestinal metaplasia 
and high-grade dysplasia. When intestinal metaplasia or high-grade dysplasia 
were present and adenocarcinoma was absent, the other sections were used for 
immunohistochemical analyses. Antigen retrieval was performed by boiling the 
deparaffinized samples in a 10 mM monocitric acid buffer (pH 6.0) in a microwave 
for 15 min, and slowly cooling down to room temperature. Subsequent samples 
were incubated in TBS buffer containing 10% rabbit non-immune serum (DAKO, 
Glostrup, Denmark), and 10% normal human plasma (DAKO) for 30 minutes. 
Primary antibodies used were anti-aldolase B (clone D18, Santa Cruz, Santa Cruz, 
CA) in a 1:200 dilution, anti-FABP1 (clone L2B10, Monosan, Uden, The Nether-
lands) in a 1:500 dilution, anti-cytokeratin 4 (clone 6B10, Monosan) in a 1:50 di-
lution, anti-cytokeratin 13 (clone 1C7, Monosan) in a 1:50 dilution, anti-calgranu-
lin A (clone CF-145, Chemicon International,Temecula CA, USA) in a 1:50 dilution, 
and anti-calgranulin B (clone C-19, Santa Cruz) in a 1:40 dilution. Detection was 
performed with secondary biotin-labeled antibodies, rabbit-anti-goat (DAKO) and 
rabbit-anti-mouse (DAKO), followed by the addition of a streptavidine-alkaline 
phosphatase complex (DAKO) using fast blue as substrate.
RESULTS
Differential gene expression
Since it is difficult to obtain sufficiently large paired biopsy samples falling within 
our inclusion criteria, transcription profile analysis was limited to the material of 
four representative patients. Paired jumbo biopsies from BE, and HGD were ob-
tained and immediately divided in three parts; the inner part was flashfrozen in 
liquid nitrogen and stored for subsequent use in transcription profiling analysis, 
while the two flanking parts were submitted for histological examination by two 
independent expert pathologists. Only for one of these four patients flanking parts 
matched all of our rigorous inclusion criteria: i.e. the BE sample did neither con-
tain LGD or HGD, nor squamous epithelium, and in the HGD sample more than 
fifty percent of the epithelium was high-grade dysplasia and infiltrating adenocar-
cinoma was not present. The two frozen midsections of the two samples (BE and 
HGD) of this single patient were then used for RNA isolation and the differences 
in mRNA levels between these two samples were determined for all 11835 genes 
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present on the Atlas human 12K microarray. Briefly, 866 of 11835 genes (7.3%) 
displayed a significant (2-fold or greater) difference in mRNA levels between the 
two samples. As this is more than can be dealt with in a reasonable amount of 
time it was arbitrarily selected to further analyze only the 33 genes (0.3%) that 
showed a greater than 10-fold difference. The microarray results for these 33 
genes are summarized in Table 3. The results for all tested genes will be made 
available as supplementary data.
Calgranulin A and B are differentially expressed in BE and HGD
A total of 22 genes predominantly involved in gastrointestinal processes and in-
flammation were selected to further analyze mRNA transcription. mRNA levels 
were determined by semi-quantitative RT-PCR in 21 BE and 5 HGD biopsies, as 
well as in 21 biopsies of the squamous epithelium 5 cm above the Z-line, and 8 
advanced adenocarcinoma biopsies. Relative expression levels are listed in Table 
4 and PCR results for a representative set of biopsies are shown in Figure 1a. 
Overall, both experimental setups displayed similar trends. Statistical analyses re-
vealed a significant difference between BE and HGD for only 2 genes, calgranulin 
A and calgranulin B (Figure 1b and c). In other samples there was a trend towards 
up- or downregulation in HGD, but this did not reach significance. In the squa-
mous epithelium calgranulin A and B mRNA levels were also significant increased 
compared to BE (p<0.001). 
Differences in protein expression and localization
To determine the effect of the differential gene expression on both protein ex-
pression levels and location, an immunohistochemical analysis was performed 
on archival material of 9 patients with BE and 9 patients with HGD. The 6 genes, 
which showed largest differences between BE and HGD in RT-PCR were tested. In 
serially sectioned slides calgranulin A (S100A8), calgranulin B (S100A9), aldolase 
B, fatty acid binding protein 1 (FABP1), and cytokeratins 4 and 13 protein expres-
sion was determined. Adjacent Haematoxylin and Eosin stained slides were used 
to identify the regions with HGD and intestinal metaplasia. Calgranulin A expres-
sion was mainly observed in neutrophilic granulocytes. In the majority of patients, 
staining was also observed in the columnar epithelium, albeit less intense. In non-
dysplastic columnar cells cytoplasmic staining was limited to the basal side of the 
cytoplasm, but in high-grade dysplastic columnar cells the entire cytoplasm was 
stained.
  To exclude that the differences in mRNA levels were due to differences in inflam-
mation, the number of infiltrating neutrophils was determined, and no significant 
difference was found (p>0.05). Calgranulin A was also intensely expressed in 
small islands of squamous epithelium present in some slides (Figure 2a and b). 
Calgranulin B expression was observed in the same areas as calgranulin A, but 
staining was more intense, probably due to aspecific background staining of the 
antibody (Figure 2c and d). Aldolase B expression (Figure 2e and f) was predomi-
nantly observed in the cytoplasm of columnar cells, but did not differ between 
BE and HGD. No staining was observed with either cytokeratin 4 or cytokeratin 
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Table 3. Genes with a more than 10-fold difference between BE and HGD in 
microarray performed on biopsy material from a 53-year old male patient*
mRNA levels Microarray
Genes BEa HGDb Ratio BE/HGD
Gastric
Pepsinogen A 2485 13 191 
CA11 1902 14 136 
TFF1 36222 692 52 
Gastric lipase 13344 419 32 
TFF2 1817 80 23 
H+K+ ATP-ase 580 42 14 
MUC5B 577 50 12 
Pepsinogen C 4599 451 10 
Intestinal
Fatty acid binding protein 2 161 13 12 
Hydroxysteroiddehydrogenase 2 315 28 11 
Hepatic
Fatty acid binding protein 1 1484 13 114 
Aldolase B 1546 53 29 
Pancreatic
Chymotrypsinogen B1 4036 13 310 
Colipase 2240 23 97 
Elastase 3A 1603 18 89 
Carboxypeptidase B1 780 13 60 
Carboxylester lipase 838 30 28 
Phospholipase A2 1249 52 24 
Trypsin 2 16311 976 17 
Tumor related
Prostate stem cell antigen 1901 28 68 
Chromogranin A 253 23 11 
Ret proto-oncogene 535 52 10 
Dual specificity phosphatase 1 47 536 0.088
Inflammatory
Calgranulin B (S100A9) 77 799 0.096
Calgranulin A (S100A8) 199 5056 0.039
Psoriasin (S100A7) 17 1557 0.011
Miscellaneous
Transthyretin 408 15 27 
Integral membrane protein 2B 1652 126 13 
Cytokeratin 13 43 438 0.098
Junction plakoglobin 185 2186 0.085
Thioredoxin 58 691 0.084
Cytokeratin 4 180 2257 0.080
Ribosomal protein P1 225 3581 0.063
a BE = Non-dysplastic Barrett’s esophagus
b HGD = Barrett’s esophagus with high-grade dysplasia
* A list of genes that showed a > 2-fold difference is published on www.gastrolab.nl
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Table 4. Relative mRNA levels of 22 differentially expressed genes determined by 
semi-quantitative RT-PCR 
mRNA levels Semi-quantitative RT-PCR
Gene products Sq 
(n = 21)a
BE 
(n = 22)b
HGD 
(n = 5)c
EAC
(n = 8)d
p-value 
BE - HGDe
Gastric
Pepsinogen A 0.01 0.09 0.07 0.52 0.9
CA11 0.01 0.02 0 0.05 0.48
TFF1 0.24 2.00 1.59 1.85 0.85
Gastric lipase 0.15 0.78 0.75 0.49 0.9
TFF2 0.35 2.21 1.86 1.98 0.71
H+K+ ATP-ase 0.01 0.15 0 0.09 0.2
MUC5B 0.03 0.54 0.62 0.77 0.83
Pepsinogen C 0.10 0.47 0.47 0.87 0.37
Intestinal
Fatty acid binding protein 2 0.03 0.62 0.04 0.26 0.11
Hydroxysteroiddehydrogenase 2 0.04 0.91 0.74 0.47 0.9
Hepatic
Fatty acid binding protein 1 0.02 1.09 0.77 0.35 0.57
Aldolase B 0.11 0.69 0.23 0.13 0.57
Tumor related
Prostate stem cell antigen 1.74 1.82 1.29 0.89 0.32
Inflammatory
Psoriasin 0.94 0.31 0.78 0.70 0.24
Calgranulin A 3.31 0.79 1.75 1.04 0.02*
Calgranulin B 4.01 0.82 1.81 1.06 0.02*
Miscellaneous
Ribosomal protein P1 2.71 2.09 2.04 2.18 0.35
Cytokeratin 4 2.45 0.50 0.66 0.06 0.26
Junction plakoglobin 0.36 0.18 0.40 0.88 0.36
Cytokeratin 13 3.79 0.85 1.56 0.37 0.23
Transthyretin 0 0.05 0 0.05 0.49
Integral membrane protein 2B 1.39 1.19 1.09 1.59 0.67
a Sq = squamous epithelium
b BE = non-dysplastic Barrett’s epithelium
c HGD = high-grade dysplasia
d EAC = esophageal adenocarcinoma
e Statistics were performed using the Mann-Whitney U-test. A p-value of < 0.05 was considered significant 
(*)
13 in BE or HGD. However, the squamous epithelium that was present in some 
slides always showed intensive cytokeratin 4 and 13 staining (data not shown). 
FABP1 expression was observed in the top of some villi. In BE, FABP1 protein was 
present in the entire top of the villus, while in HGD it was observed in only a few 
cells (Figure 2g and h).
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DISCUSSION
The identification of genes involved in the development of high-grade dysplasia 
in Barrett’s esophagus can potentially help to increase our understanding of the 
development of early neoplastic lesions in Barrett’s esophagus. In esophageal 
carcinogenesis, various proto-oncogenes, and tumor-suppressor genes have been 
studied and some of them, like p53, and MUC4 have indeed been implicated in 
the development of HGD [6, 10]. However, up to now, no genetic marker can be 
used to completely distinguish BE from HGD in 100% of patients [11]. This may 
indicate that there is probably not a single pathway involved in the development 
of HGD. 
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Figure 1   Representative RT-PCR results 
of calgranulin A and B on biopsies of squa-
mous epithelium (Sq), non-dysplastic Bar-
rett’s esophagus (BE), high-grade dysplasia 
(HGD), and esophageal adenocarcinoma 
(EAC) from the same patient (A). Graphic 
representation of calgranulin A and B rela-
tive mRNA levels in Sq, BE, HGD, and EAC 
(B and C). 
Figure 2   Haematoxylin and eosin stained control sections for high-grade dysplasia (HGD) (A) and 
non-dysplastic Barrett’s esophagus (BE) (B). In HGD, calgranulin A is present in the entire cytoplasm 
(C, arrow), while in BE it was only observed on the basal site of the cell (D, arrow). Staining patterns for 
calgranulin B in HGD (E) and BE (F) resemble those of calgranulin A, except for an intense background 
staining probably due to aspecific staining of the polyclonal antibody. FABP1 is present in a small subset 
of cells in HGD (G, arrow), while it was observed in the entire top of the villus in BE (H). A color version 
of this figure is printed on page 117.
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  In this study differential gene expression analysis of a single rigidly selected 
sample was used to identify genes that have thus far not been implicated in the 
development of HGD. From this patient, paired biopsy samples containing either 
BE or HGD were obtained. The use of paired samples for transcriptional profiling 
analysis excludes interpatient variability thus generating more reliable data. As it 
proved impossible to obtain more large paired biopsy samples falling within our 
inclusion criteria within a reasonable time period we decided to test a selection of 
the most prominently differentially transcribed genes. Therefore two completely 
independent methods were used, i.e. semi-quantitative RT-PCR, and histology 
based comparison of protein expression and localization in a large set of biopsy 
samples, obtained from 41 Barrett’s esophagus patients with or without dysplasia 
or adenocarcinoma. 
  The analysis of the transcription profiles of BE and HGD from this single patient 
revealed a 10-fold or greater difference in mRNA levels for 33 genes. To exclude 
false-positive results that are often generated by array techniques, mRNA levels 
of 22 of the identified genes were tested by semi-quantitative RT-PCR in paired 
samples of 23 patients, and by immunohistochemistry in 18 patients. Although 
the data (with regard to fold-increase) obtained by these two techniques can by 
no means be directly compared, one of the important findings was that the RT-
PCR results revealed that calgranulin A and calgranulin B were significantly up-
regulated in HGD compared with BE, and that none of the genes was significantly 
downregulated in HGD. For the 20 other tested genes, the same trends as in the 
microarray analysis were observed, however, the sample size was not big enough 
to achieve significant differences. Apart from increased mRNA levels, the immuno-
histochemical analysis revealed also an increase in cytoplasmic calgranulin A and 
B protein levels in HGD compared to BE. 
  Strikingly, both calgranulin A and calgranulin B exert most of their functions in 
a heterodimer, which is called calprotectin. They are members of the S100 fam-
ily of calcium-binding proteins, and they are also known as S100A8 and S100A9, 
respectively. Calprotectin is mainly expressed in neutrophilic granulocytes and 
monocytes, where it is involved in cell trafficking to inflammation sites by influ-
encing chemotaxis and endothelial adhesion, as are the undimerized subunits. 
Furthermore the complex is able to transport poly-unsaturated fatty acids such 
as arachidonic acid [12-14]. The expression of calgranulin A and B is however not 
limited to inflammatory cells, but it is also observed in keratinocytes and other 
epithelial cells such as squamous epithelium of the esophagus. In these tissue 
types, the dimer seems to have a role in wound healing [15, 16], thus linking this 
protein with proliferative activities.
  In this study, calgranulin A and B expression was not only observed in neu-
trophilic granulocytes, but also in esophageal squamous cells and columnar cells 
of patients with Barrett’s esophagus. Its presence in these cells may be caused by 
the presence of reactive oxygen species (ROS), since calgranulin A is induced by 
ROS and increased amounts of ROS have been demonstrated in esophageal squa-
mous and columnar epithelium [17, 18]. Furthermore, calprotectin interacts with 
NADPH oxidase, which generates the superoxide anion, to transfer arachidonic 
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acid, a cofactor of this enzyme [19, 20].
  Barrett’s esophagus is not the only chronic inflammatory lesion in which calgran-
ulin A and B are overexpressed. Increased amounts of the calprotectin complex 
have also been observed in Crohn’s disease and the complex is currently used as 
diagnostic marker for the severity of inflammation [21]. Increased calgranulin 
expression has also been found in several malignancies, including gastric tumors, 
but its exact role in carcinogenesis is unknown [22, 23]. One explanation could 
be that in HGD increased amounts of ROS are present, resulting in an upregu-
lation of calgranulin A. However, the fact that both subunits of the calprotectin 
heterodimer are upregulated in HGD and that the genes encoding calgranulin A 
and B are located in the same chromosomal region, suggest a common regulatory 
mechanism for both subunits. Since calgranulin A and B are not only expressed 
in neutrophilic granulocytes, but also in the columnar esophageal cells, the differ-
ences in expression could not only be due to an increase in influx of inflammatory 
cells, but also to elevated epithelial expression. Therefore we hypothesize that the 
calprotectin complex is involved in the proliferation of neoplastic cells, thus gen-
erating neoplastic growth in Barrett’s esophagus. This hypothesis is supported by 
the proliferative role in wound healing [15, 16].
  The identification of several differentially expressed proteins in this study dem-
onstrate the value of new profiling techniques, such as microarray, in the elucida-
tion of new molecular markers for early neoplastic lesions. Along with other dif-
ferentially expressed proteins, such as p53, E-cadherin and MUC4 [6, 7, 10], the 
differentially expressed proteins may be part of an array-like diagnostic test, that 
can facilitate the detection and diagnosis of high-grade dysplasia. Such tests have 
already been developed for breast-cancer [9].
  In conclusion, we have here reported on the differential gene expression between 
Barrett’s esophagus without dysplasia and Barrett’s esophagus with high-grade 
dysplasia. The fact that both subunits of the calprotectin complex, calgranulin A 
and B were elevated in HGD, suggests that calprotectin may play a role in the in-
duction of proliferation of dysplastic columnar cells in Barrett’s esophagus.
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ABSTRACT
Barrett’s esophagus is a premalignant condition that is characterized by chronic 
inflammation, initiated by gastroduodenal reflux. The inflammatory process is 
probably started and maintained by chemokines, which are chemotactic cytokines 
that control leukocyte trafficking during inflammation and neoplastic growth, and 
may attract neutrophils, T-cells, B-cells, and plasma-cells to the site of inflamma-
tion. In this study the effect of bile acids on the expression of key chemokines 
MCP-1 (CCL2), RANTES (CCL5), MIP-3α (CCL20), MEC (CCL28), and IL-8 (CXCL8) 
was determined in esophageal cell lines, as well as in 89 esophageal biopsies ob-
tained from patients with reflux esophagitis, Barrett’s esophagus and esophageal 
adenocarcinoma. Exposure of cultured epithelial cells (TE7 and OE21) to deoxy-
cholic acid resulted in increased transcription and expression of MEC, MIP-3α, and 
IL-8, whereas transcription of MCP-1 and RANTES was not altered. In contrast, 
exposure to taurodeoxycholic acid did not result in increased chemokine mRNA 
levels. Similar transcriptional patterns were also found in biopsies obtained from 
patients with reflux esophagitis, Barrett’s esophagus and esophageal adenocar-
cinoma. MCP-1 mRNA levels were increased in both reflux esophagitis and Bar-
rett’s esophagus, while MIP-3α and MEC mRNA levels were increased in Barrett’s 
esophagus. MIP-3α mRNA levels increased with progressive histological stages 
of adenocarcinoma development. In conclusion, the expression of several key 
chemokines increases during the progression from metaplasia to dysplasia and 
adenocarcinoma, a process mimicked in vitro by incubation with deoxycholic acid. 
This suggests an important role for biliary reflux in the initiation and maintainance 
of the inflammatory response in Barrett’s esophagus and esophageal adenocar-
cinoma.
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INTRODUCTION
Barrett’s esophagus (BE) is a premalignant condition that is characterized by the 
replacement of the normal squamous epithelium of the lower oesophagus by spe-
cialized columnar epithelium of the intestinal type. Esophageal adenocarcinoma 
(EAC) is thought to develop in BE in a stepwise manner via low-grade dysplasia 
(LGD) and high-grade dysplasia (HGD) [1]. Gastroesophageal reflux is believed 
to play an important role in causing BE [2]. Upon exposure to the refluxate, the 
normal squamous mucosa of the esophagus will become inflamed, which is called 
reflux esophagitis (RE). In ten percent of these patients, the inflamed squamous 
epithelium will be replaced by columnar epithelium of the intestinal type, which is 
inflamed as well [3].  
  Epithelial cells play an important role in inducing an inflammatory response. The 
exposure of the esophageal mucosa to the refluxate can result in the epithelial 
production of inflammatory mediators that promote the influx of leukocyte sub-
sets, thus inducing an inflammatory response. The specific chemokines that are 
secreted by the epithelial cells regulate the composition of the leukocyte influx by 
binding to the specific chemokine receptors on the cell surface of the leukocytes 
thereby promoting chemotaxis. Leukocytes that are abundantly present in the 
Barrett’s epithelium are neutrophils, T-cells, and plasma-cells (Moons et al. in 
press). The composition of the secreted chemokine pool is often a good marker 
for monitoring and studying the inflammatory process in chronic inflammatory 
lesions, such as inflammatory bowel disease and chronic hepatitis C infection [4, 
5]. Examples of key chemokines are MCP-1 (CCL2) and RANTES (CCL5), which 
both attract monocytes and T-cells, MIP-3α (CCL20), which attracts dendritic cells 
and activated B-cells; MEC (CCL28), which attracts plasmacells, and IL-8 (CXCL8), 
which mainly attracts neutrophils [6].
  It is generally accepted that the main cause of inflammation in the esophagus 
is gastroesophageal reflux. The major components of the gastroduodenal reflux-
ate are gastric acid and bile acids, which are irritants for the esophageal mucosa. 
Bile and gastric acid were demonstrated to have proliferative and anti-apoptotic 
effects on the esophageal mucosa in vitro and ex vivo [7, 8]. Of the bile acids, 
deoxycholic acid (DCA) and its conjugated forms are principal components of the 
gastroduodenal refluxate in patients with BE [9]. It has been reported that DCA is 
involved in the upregulation of inflammatory proteins such as cyclooxygenase-2 
and IL-8 in BE [10, 11]. Since DCA is involved in reflux-induced cell irritation, and 
this irritation leads to the attraction of inflammatory cells, we hypothesize that 
deoxycholic acid could induce the expression of several chemokines. 
  Elevated levels of chemokines MCP-1, RANTES and IL-8 have been observed 
in RE compared to normal squamous epithelium of the esophagus [12], but de-
spite of their crucial role in the induction and maintenance of the local immune 
response, the chemokine expression pattern in BE, or EAC has to our knowledge 
not been reported thus far. 
  The aim of this study was to test the hypothesis that bile acids drive the ex-
pression of key chemokines MCP-1, RANTES, MIP-3α, MEC, and IL-8, and to test 
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whether these chemokines are differentially expressed over the esophagitis-
metaplasia-dysplasia-carcinoma sequence.
MATERIALS AND METHODS
Patients
A total of 89 biopsies from 50 patients with RE, BE without dysplasia, dysplasia or 
EAC were included. Patient and sample characteristics are outlined in Table 1. En-
doscopic patient evaluation, and biopsy collection and histopathologic assessment 
were according to routine standard procedures. Biopsies were obtained from the 
normal squamous epithelium (Sq), RE, BE, and, when present, from LGD, HGD, 
or EAC. Adjacent biopsies were analyzed by an experienced GI pathologist, who 
evaluated haematoxylin and eosin stained sections for the presence of intestinal 
metaplasia, grade of dysplasia, or EAC. This study was approved by the local ethi-
cal review board of the Erasmus MC - University Medical Center Rotterdam and 
informed consent was obtained from patients prior to endoscopy.
Table 1. patient characteristics
 
patientgroups patients Mean age 
(range)
% male Biopsies obtained
Sqa REb BEc LGDd HGDe EACf
RE 11 52.8 (37-68) 64 0 11 0 0 0 0
BE 12 60.9 (42-85) 67 12 0 12 0 0 0
dysplasia 11 67.6 (53-79) 82 2 0 0 6 8 0
EAC 16 64.1 (44-79) 69 7 0 5 4 6 16
Total 50 21 11 17 10 14 16
a Sq: Normal squamous epithelium of the esophagus
b RE Reflux esophagitis
c BE: Non-dysplastic Barrett’s esophagus
d Barrett’s esophagus with low-grade dysplasia
e Barrett’s esophagus with high-grade dysplasia
f EAC: Esophageal adenocarcinoma
Semi-quantitative RT-PCR
Total RNA was isolated from Sq, RE, ND, LGD, HGD and EAC biopsies using Trizol-
reagent (Invitrogen, Paisley, UK) and remaining traces of chromosomal DNA were 
eliminated using the DNA-free RNA kit (Zymo, Orange, CA, USA) [13]. cDNA was 
synthesized with the use of Avian Myeloma Virus reverse transcriptase according 
to the instructions of the manufacturer (Promega, Madison, WI, USA), by incubat-
ing 10 ng total RNA with reverse trancriptase for 30 min at 42°C. PCR-reactions 
(total volume of 25 μl) contained 1 μl of the cDNA solution, 1x PCR  buffer (Roche 
Diagnostics, Mannheim, Germany), 2 mM magnesium chloride, 0.4 µM forward 
and reverse primer, 200 µM of each nucleotide (Roche Diagnostics) and 0.02 U/μl 
C
ha
pt
er
 8
94
Chemokines in Barrett’s esophagus 95
Taq polymerase (Roche Diagnostics). All primers were designed with aid of primer 
designer software (Clone Manager, version 5.10, Scientific and Educational soft-
ware) using sequences from the NCBI database (www.ncbi.nlm.nih.gov), and are 
listed in Table 2. PCR conditions were 35 cycles at 94°C (30 s); 50-55°C (30 s) 
and 72°C (1 min). PCR-products were visualized on a 2% agarose gel and stained 
with ethidiumbromide. Band size and intensity were determined by densitometry 
with Kodak 1D version 3.5 software (Kodak, New Haven, CT, USA) and data were 
normalized using the housekeeping gene β-actin, as described previously [14]. 
RT-PCR densitometric data are presented as mean ± standard error of the mean. 
Statistical analyses were performed using SPSS software (version 11.0, SPSS 
Inc), using the Mann-Whitney U-test. A p-value < 0.05 was considered statisti-
cally significant.
Cell culture
The esophageal adenocarcinoma cell-line TE7 [15], and the esophageal squamous 
cell carcinoma cell-line OE21 [16] were kindly provided by dr. George Triadafilo-
poulos, Stanford University, Palo Alto, CA, USA. These cell-lines are internationally 
accepted and widely used tools for representation of the esophagus epithelium. 
Both cell-lines were cultured in RPMI 1640 with L-glutamine (Bio Whittaker, Verv-
iers, Belgium) supplemented with 10% Fetal Calf Serum (Hyclone, Logan, UT, 
USA), and 20 units/ml penicillin/streptomycin. Cells were maintained as a sub-
confluent monolayer in a 75 cm2 tissue culture flask in a humidified incubator with 
5% CO2 at 37°C. 
RNA analysis of cells incubated with bile acids and acid
Cells were seeded at 0.4 x 106 cells/well in a six-well plate and incubated for 24h 
at 37°C. Subsequently, cells were incubated for 20 minutes with RPMI medium 
containing 10% fetal calf serum, L-glutamine and penicillin/streptomycin that was 
supplemented with 0.2 mM taurodeoxycholic acid (TDCA), 0.2 mM DCA, either at 
neutral pH or pH5.5, or control medium. Cells were harvested with a trypsin/EDTA 
solution (Gibco, Paisley, UK), cells were washed twice in control medium, and 
lysed in Trizol. RNA isolation and RT-PCR was performed as described above. Cell 
viability was determined by staining with tryphan blue. Only experiments with a 
Table 2. PCR-Primers
Gene Forward primer Reverse Primer T a
MCP-1 5’TCCTGTGCCTGCTGCTCATAG3’ 5’TTCTGAACCCACTTCTGCTTG3’ 50°C
RANTES 5’ATGAAGGTCTCCGCGGCA3’ 5’CCTAGCTCATCTCCAAAGAGTTG3’ 55°C
MIP-3α 5’ATGTCAGTGCTGCTACTC3’ 5’TGTCACAGCCTTCATTGG3’ 50°C
MEC 5’AGAAGCCATACTTCCCATTGC3’ 5’AGCTTGCACTTTCATCCACTG3’ 50°C
IL-8 5’GTGGCTCTCTTGGCAGCCTTCTGAT3’ 5’TCTCCACAACCCTCTGCACCCAGTTT3’ 55°C
β-actin 5’GACAGGATGCAGAAGGAGAT3’ 5’AGTCATAGTCCGCCTAGAAG3’ 55°C
a Temperature used for annealing of this primers
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cell viability of 90% or more at the end of the experiment were included in the 
analyses. For both OE21 and TE7 cells three independent experiments were per-
formed.
Chemokine protein level determination
TE7 cells were seeded at 0.4 x 106 cells/well in a six-well plate and incubated for 
24h at 37°C. Subsequently, cells were incubated for 32 hours with RPMI medium 
containing 10% fetal calf serum, L-glutamine and penicillin/streptomycin that 
was supplemented with 0.2 mM DCA, or control medium. Aliquots of the culture 
medium were taken at t=0, t=1, t=2, t=4, t=8, t=12, t=24, and t=32 hours and 
were frozen until chemokine concentration determination. Protein concentrations 
of IL-8 and MIP-3α were determined by using standardized ELISAs for IL-8 (Bio-
source international, Nivelles, Belgium), and MIP-3α (R&D systems, Minneapolis, 
MN), according to the instructions of the manufacturer. 
RESULTS
DCA induces chemokine transcription and expression in cell-lines
Gastroesophageal reflux contains both gastric acid and bile acids. To determine 
the effect of bile acids on chemokine transcription in the esophagus, an interna-
tionally well-accepted esophageal cell culture model was used. TE7 adenocar-
cinoma cells and OE21 squamous cell carcinoma cells were exposed to tissue 
culture medium supplemented with TDCA or DCA at predetermined physiological 
concentrations, or unsupplemented control medium, at a neutral pH. The bile 
acid concentrations and incubation times were deduced from the in vivo condi-
tions during reflux episodes. Lower concentrations and shorter incubation times 
resulted in a less pronounced effect, while higher concentrations affected the cell 
viability. MCP-1 mRNA levels were below the detection limit in OE21 and TE7 cells. 
RANTES transcription was detected in OE21 cells, but not in TE7 cells, however 
TDCA and DCA did not induce RANTES mRNA levels. In contrast, MIP-3α, MEC, 
-actin
MCP-1
RANTES
MIP-3
IL-8
MEC
TDCA
- +
DCA
- +
OE21
TDCA
- +
DCA
- +
TE7
Figure 1   Representative RT-PCR 
results of  bile acid assays. OE21 and 
TE7 cells incubated with 0.2 mM tau-
rodeoxycholic acid (TDCA), 0.2 mM 
deoxycholic acid (DCA), or control 
medium for 20 min.        
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and IL-8 transcription was induced by DCA in both OE21 and TE7 cells. Incubation 
with equal concentrations of TDCA did not induce transcription of any of the tested 
chemokines (Figure 1). 
  Incubation of TE7 cells with DCA resulted also in increased expression of IL-8 and 
MIP-3α protein (Figure 2). After 4 hours of incubation, IL-8 production, and after 8 
hours of incubation MIP-3α production of cells incubated with DCA was significant 
elevated compared to cells incubated with control medium (p = 0.05). 
To determine the effect of pH, TE7 cells were cultured at pH7.4 and pH5.5 in the 
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Figure 2   Graphic representation of A IL-8 and B MIP-3α production in culture supernatant of TE7 cells 
incubated with DCA (dotted line) or control medium (continuous line) at different time points during 32 
hour of incubation.
presence and absence of DCA. Increased transcription of MEC was detected in 
cells cultured at pH7.4 with DCA and at pH5.5 without DCA. Surprisingly, DCA was 
not able to induce MEC transcription at pH5.5 (Figure 3). A pH lower than pH5.5 
affected the cell viability.
MEC
C  DCA
pH 7.4 pH 5.5
-actin
C  DCA
Figure 3   MEC transcription in TE7 cells incubated with either 
acid (pH5.5) and DCA alone, a combination of acid (pH 5.5) and 
bile, or control medium (C). 
Chemokine mRNA levels in biopsies
To investigate whether the changes in chemokine transcription in vitro were 
matched in vivo, chemokine mRNA levels were determined in biopsies of the vari-
ous esophageal disease stages. MCP-1 mRNA levels were significantly increased 
in RE (p = 0.007) and BE (p = 0.001) compared to Sq and levels were even more 
increased in EAC (Figure 4a). RANTES mRNA levels were not different between the 
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Figure 4   Graphic representation of relative mRNA levels 
in squamous epithelium (Sq), reflux esophagitis (RE), 
Barrett’s esophagus (BE), low-grade dysplasia (LGD), 
high-grade dysplasia (HGD), and esophageal adenocar-
cinoma (EAC). mRNA levels of the specific chemokines 
were normalized against the mRNA levels of a house-
keeping gene, β-actin, using densitometry, which gains 
relative mRNA levels. Statistics were performed using the 
Mann-Whitney U-test and p < 0.05 was considered signi-
ficant. A MCP-1, B RANTES, C MIP-3α, D MEC, and E IL-8
several stages (Figure 4b), but MIP-3α was increased in BE compared to Sq and RE 
(p < 0.001) and increased even more in EAC (p = 0.007) (Figure 4c). MEC was sig-
nificantly increased in BE compared to RE (p < 0.001). In contrast, in LGD, HGD, 
and EAC, MEC levels were decreased compared to BE, and increased compared 
to Sq and RE (Figure 4d). IL-8 was gradually increased along the Sq – BE – LGD 
– HGD – EAC sequence, but due to the large variation in the groups, only mRNA 
levels in EAC were significantly increased when compared to Sq (Figure 4e). 
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DISCUSSION
The chronic inflammation in BE and RE is most likely initiated and maintained by 
the exposure to the gastroduodenal refluxate, containing mainly gastric acid and 
bile. In this study an in vitro cell culture model was used to determine the effect of 
the secondary bile acid DCA and its taurine conjugate on chemokine transcription. 
It was observed that DCA, but not TDCA, induced the transcription and expression 
of IL-8, MIP-3α, and MEC, in both an esophageal squamous carcinoma cell-line 
and an adenocarcinoma cell-line. MCP-1 and RANTES were not induced by this bile 
acid. MCP-1 and RANTES are not secreted by all types of epithelial cells, which 
could explain the failure to detect RANTES in one and MCP-1 in both cell-lines. The 
presence of these chemokines in RE and BE could be explained by their secretion 
by inflammatory cells.
  DCA is one of the most toxic components of the bile refluxate. It is generally 
believed that DCA is involved in carcinogenesis, since it can induce proliferation 
in animal models and since increased serum levels were observed in patients 
with colorectal cancer [17, 18]. DCA is able to induce DNA damage in esophageal 
cells [19]. DCA and TDCA have different effects on the transcriptionfactor NF-κB, 
which is probably involved in the transcription of these chemokines. It has been 
reported that DCA can activate NF-κB by degradation of one of its subunits, while 
TDCA acts mainly by phosphorylation of the protein [20]. This can explain the 
differences between these bile acids in the ability to induce chemokine transcrip-
tion. Another explanation for this difference can be that TDCA is able to penetrate 
the membrane, while DCA may act on a membrane bound receptor, probably the 
epidermal growth factor receptor [21], thereby initiating a signalling cascade that 
probably leads to the transcription of chemokines.
  The effect of acid (pH5.5) was the same as that of DCA. However, the combi-
nation of acid and bile failed to induce transcription of the chemokine MEC. An 
antagonistic effect of acid on induction of inflammatory mediators such as pros-
taglandins and COX2 has been reported before [7, 22]. An explanation for this 
phenomenon could be that a lower pH alters the binding capacity of DCA to a 
membrane receptor through which it exerts its effect. 
  Although the cell-line model with immortalized cancer cells is a limited represen-
tation of the real RE and BE, these results imply that DCA plays a key role in the 
induction of an immune response in BE and RE. Moreover, they demonstrate the 
important role of epithelial cells in the recruitment of the immune system.
  To study the role of chemokines MCP-1, RANTES, MIP-3α, MEC, and IL-8 in vivo, 
their transcription was determined in different esophageal disease stages of the 
development of RE, BE and EAC. It was observed that mRNA levels of MCP-1, MIP-
3α, MEC, and IL-8 were elevated in BE compared to normal squamous epithelium. 
These chemokines attract a subset of inflammatory cells that are abundantly 
present in BE, while the normal squamous epithelium is not chronically inflamed. 
MIP-3α and MEC are also significantly elevated in BE compared to RE. 
  Although RE and BE are both chronic inflammatory lesions, the inflammatory re-
spons is slightly different. Reflux esophagitis is characterized by the expression of 
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proinflammatory cytokines such as IL-1β and IFNγ, a T-helper 1 (Th1) response, 
while in BE anti-inflammatory cytokines IL-4 and IL-10 are induced, which is a Th2 
profile [23]. The differences in chemokine levels may lead to an altered T-helper 
response. For instance, the the increase in MCP-1 may lead to Th2 skewing [24], 
thereby stimulating the humoral immune response, while Th1 cells, which are at-
tracted by RANTES, are not increasingly recruited.
   Chronic inflammation, and in particular the innate immune response has also an 
important role in cancer development [25]. Cells of the innate immune response, 
such as monocytes, macrophages and neutrophils infiltrate in tumor tissues where 
they can be involved in extracellular matrix degradation by the upregulation of 
matrix metalloproteinases [26]. Chemokines, i.e. MIP-3α and IL-8, can trigger 
the release of these compounds from the immune cells, suggesting an active role 
in angiogenesis, tumor growth and metastasis [27, 28]  [29]  [30]. In this study 
this was illustrated by the increased MIP-3α and IL-8 mRNA levels in EAC. Other 
tumor-promoting cells that are part of the innate immune response are tumor-
associated dendritic cells. These cells are defective in their ability to stimulate 
anti-tumor T-cells. It has been reported that MIP-3α is involved in the attraction 
of these dendritic cells [31]. 
  Recently it has been shown that the adaptive immune system has also a role in 
carcinogenesis. It has been reported that the humoral immune response has an 
important role in tumor formation in chronically inflamed tissue [32]. The main 
cells in the humoral immune response are B-cells that are activated and prolifer-
ate to antibody secreting plasmacells. These cells are attracted by MIP-3α and 
MEC. Increased levels of these chemokines can lead to increased influx of B-cells 
and plasmacells and the antibodies they produce into the tumor environment, 
thereby promoting tumor formation.
  MIP-3α seems to have many roles in carcinogenesis. EAC is not the only tumor 
type in which increased levels of this chemokine has been demonstrated. Elevated 
levels of MIP-3α has also been reported in pancreatic and hepatocellular carci-
noma [33, 34]. Moreover, MIP-3α was observed in other premalignant chronic 
inflammatory lesions such as inflammatory bowel disease and chronic hepatitis 
[35, 36].
  Chemokines have only recently been discovered as chemotactic agents involved 
in inflammation and tumorigenesis, but are already considered promising tar-
gets for therapeutic intervention. Analogous to the anti-cytokine based therapies 
that are currently under investigation for chronic inflammatory diseases such as 
inflammatory bowel disease and rheumatoid arthritis, antibody based therapies 
against chemokines, such as IL-8 are under development and have promising re-
sults in preliminary pilot studies [37]. Anti-IL-8 based therapy does not only have 
anti-inflammatory effects, but it induces also tumor regression in mice [38]. The 
current study shows that the targets for anti-chemokine therapy are present and 
that in the future this therapy may have perspectives for the prevention and treat-
ment of BE and EAC. Furthermore, non-steroidal anti-inflammatory drugs have 
been shown to protect against tumor development in chronically inflamed tissue 
[39]. These drugs have also been shown to protect against EAC [40].
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   In conclusion, the expression of several key chemokines increases during the 
progression from metaplasia to dysplasia and adenocarcinoma, a process mim-
icked in vitro by incubation with deoxycholic acid. This suggests an important role 
for biliary reflux in the initiation and maintainance of the inflammatory response 
in Barrett’s esophagus and esophageal adenocarcinoma.
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Barrett’s esophagus is a common disorder in the western world. It is generally 
believed that at least 1% of the inhabitants of the western world suffer from 
Barrett’s esophagus, but its incidence may well be 5% [1]. Esophageal adeno-
carcinoma is thought to develop from Barrett’s esophagus in a step-wise manner, 
via low-grade and high-grade dysplasia [2]. Gastroesophageal reflux is generally 
believed to be the major cause of Barrett’s esophagus. The reflux components, 
mainly gastric acid and bile acids, are harmful to the epithelium and it will become 
irritated. As a reaction on this irritation the normal squamous epithelium will be 
replaced by columnar epithelium that resembles the intestinal mucosa in a subset 
of patients. This epithelium, called Barrett’s esophagus, is thought to be better 
adapted to exposure to bile and acid, but it is not completely insensitive to its ac-
tion, as acid and bile apparently still induce the release of inflammatory mediators 
such as cytokines and chemokines from the epithelial cells, leading to the attrac-
tion of inflammatory cells. The continuing reflux insults establish the permanent 
presence of these inflammatory cells that results in chronic inflammation. 
  The function of the inflammatory cells is to remove the cells that are lethally 
damaged. One of the manners in which the damaged cells are killed by inflamma-
tory cells is by the secretion of reactive oxygen species. These compounds, mostly 
radicals, will cause DNA damage that sends the damaged cells into apoptosis. 
However, a few cells will survive the reflux irritation and damage by immune cells. 
The DNA damage caused by reactive oxygen species can cause mutations in genes 
involved in several processes that gives the cell a growth advantage above other 
cells and (pre)neoplastic lesions will appear. The literature that underlies this the-
ory and that describes the processes that will cause esophageal adenocarcinoma 
is reviewed in chapter 2.
THE DEVELOPMENT OF BARRETT’S ESOPHAGUS
Barrett’s esophagus is characterized by the presence of intestinal metaplasia, a 
type of metaplasia known to often progress to esophageal adenocarcinoma [3]. 
Barrett’s metaplasia resembles intestinal epithelium, both on the histological 
and molecular level. CDX2 is a homeobox protein that is specifically expressed 
in intestinal tissues and is involved in intestinal differentiation [4]. CDX2 is thus 
involved in the development of intestinal epithelium. Barrett’s esophagus resem-
bles the intestinal mucosa, and therefore we hypothesized that CDX2 expression 
was present in Barrett’s esophagus. This hypothesis was proved in chapter 3. In 
this chapter, CDX2 was not only observed in intestinal metaplasia, but also in the 
squamous epithelium of patients with Barrett’s esophagus, albeit in low amounts. 
This important finding indicates that CDX2 can mark cells that are differentiating 
to an intestinal phenotype, but do not yet have other intestinal characteristics. 
  This theory was investigated further in chapter 4 and chapter 5, in which in-
testinal metaplasia was compared to another type of columnar epithelium that 
is frequently observed in the esophagus, gastric-type mucosa. This gastric-type 
mucosa has been regarded as not related to intestinal metaplasia and not meta-
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plastic. CDX2 expression was again observed in intestinal metaplasia, but also in 
gastric-type mucosa adjacent to it and even in one third of samples that contained 
only gastric-type mucosa and no intestinal metaplasia. Since this was mainly ob-
served in patients that had small segments of intestinal metaplasia, and large 
segments of gastric-type mucosa, we suppose that in these patients a hybrid 
epithelium is present that has characteristics of both intestinal and gastric-type 
mucosa. This supports the theory that intestinal metaplasia and gastric-type mu-
cosa are related to each other. 
  Mucins are glycoproteins that protect the epithelial cells from mechanical and 
chemical damage. Every mucosa-type has a unique pattern of mucin expression. 
The expression patterns of the main mucins in Barrett’s esophagus are described 
in chapter 6. Mucins that are secreted and form a gel-like mucus layer are nor-
mally expressed in the stomach and intestine. This mucus layer protects the epi-
thelium against the chemical damage of enzymes that are secreted to digest the 
food particles. These mucins, MUC2, MUC5AC, and MUC6, were also observed in 
Barrett’s esophagus.  On the other hand, mucins that are membrane bound and 
form a protective layer on the cell-surface, MUC1 and MUC4, are expressed in the 
normal esophageal squamous epithelium, but were absent in Barrett’s esophagus. 
These results show that Barrett’s epithelium has been adapted to the harmful ef-
fect of reflux components.
  The effect of one of the principal components of reflux, bile, on the Barrett’s 
epithelium was investigated in chapter 8.  In an esophageal cell-line model cells 
were exposed to the bile acid deoxycholic acid. Exposure to deoxycholic acid, one 
of the principal and most toxic components of reflux, resulted in the enhanced 
expression of the chemokines MIP-3α, MEC, and IL-8. Chemokines are chemoat-
tractive cytokines and MIP-3α, MEC, and IL-8 attract a subset of inflammatory 
cells that have been observed in Barrett’s esophagus (Moons et al. in press). For 
instance, IL-8 attracts neutrophils, and these cells are potent producers of reac-
tive oxygen species. This bile induced chemokine production illustrate that the 
irritation caused by reflux leads to the attraction of inflammatory cells, and the 
reactive oxygen species that they produce can induce further damage.
THE DEVELOPMENT OF DYSPLASIA AND ADENOCARCINOMA IN BARRETT’S 
ESOPHAGUS
Barrett’s epithelium is metaplastic, which means that it consists of cells that are 
newly formed at a place where they do not belong. Furthermore these cells have 
to be replaced frequently due to the reflux induced irritation. Taken these two 
things together this means that this epithelium has a higher proliferative capacity 
than normal esophageal epithelium. Genetic abnormalities can be induced by the 
reactive oxygen species produced by inflammatory cells, and cells that carry this 
abnormalities are allowed to grow out, and a more active proliferating, mutation 
bearing epithelium appears. Histologically, this epithelium is also slightly different 
from the normal Barrett’s epithelium, and therefore it is called dysplasia, subdi-
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vided in low-grade dysplasia and high-grade dysplasia. The development of es-
ophageal adenocarcinoma in Barrett’s esophagus is often preceded by low-grade 
and high-grade dysplasia [2]. High-grade dysplasia seems a point of no return, as 
half of the patients will develop esophageal adenocarcinoma [5]. 
  Mucin expression often changes during neoplastic progression. The mucin pattern 
in high-grade dysplasia is described in chapter 6.  Increased MUC4 expression 
was observed in high-grade dysplasia and also in esophageal adenocarcinoma. 
MUC4 is normally expressed in esophageal squamous epithelium. Its overexpres-
sion in high-grade dysplasia and adenocarcinoma indicates that the epithelium is 
dedifferentiating, a process that is often observed during carcinogenesis. Overex-
pressed MUC4 has also several oncogenic properties. It may enhance tumorigene-
sis by masking tumor-antigens and promoting cellular detachment. It should also 
inhibit apoptosis, but this was not observed in this chapter, since it was associated 
with a pro-apoptotic balance of apoptosis proteins Bax and Bcl-2. Increased apop-
tosis is not a feature of carcinogenesis, however, high-grade dysplasia is still not 
completely derailed and by increasing apoptotic rates it may try to compensate 
for the other tumor-promoting changes. In adenocarcinoma the bax/bcl-2 balance 
shifted to a more anti-apoptotic phenotype. 
  Calgranulin A and B are also associated with high-grade dysplasia development, 
which is described in chapter 7. These proteins form together the calprotectin 
complex, that is a involved in the attraction of neutrophils that are, as stated be-
fore, potent producers of reactive oxygen species. These can cause more tumor-
promoting mutations so that adenocarcinoma can develop. Moreover, calprotectin 
is also expressed in normal squamous epithelium, where it functions in prolifera-
tion. This supports the concept of dedifferentiation in high-grade dysplasia and 
may implicate that overexpressed calprotectin increases the proliferation in high-
grade dysplasia. 
  The presence of tumor-promoting mutations in high-grade dysplasia can itself 
lead to more mutations, for instance by defects in DNA repair genes. This leads 
to the development of esophageal adenocarcinoma, a rapid growing and quickly 
metastasizing type of cancer. Chemokines can increase the metastatic potential 
of cells. MIP-3α and MEC induce the expression of matrix metalloproteinases, en-
zymes that degrade the extracellular matrix, by inflammatory cells. This enables 
the cancer cells to migrate to lymph or blood vessels and metastasize. In chapter 
8 we tested chemokine expression in adenocarcinoma samples, and increased 
MIP-3α and MEC levels were observed in esophageal adenocarcinoma. This indi-
cates that in addition to a role in chemotaxis of inflammatory cells these chemok-
ines may also function in promoting metastasis. 
CLINICAL IMPLICATIONS
Understanding the role of inflammation and the molecular alterations that occur 
during development of Barrett’s esophagus will provide new insights for the pre-
vention and treatment of this lesion. Moreover, the molecular changes that mark 
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the presence of dysplasia and adenocarcinoma can be used to diagnose the pres-
ence of malignant cells.
  Inflammation is a target for many drugs, such as NSAIDs and steroids. It is also 
an aria in which many new drugs are under development. The identification of in-
flammatory mediators that play a role in the pathogenesis of Barrett’s esophagus 
provide new targets for anti-inflammatory drugs. Commonly used drugs such as 
NSAIDs interfere with inflammatory pathways thereby decreasing inflammation. 
With the elucidation of the inflammatory profile of Barrett’s esophagus, targets 
for commonly used inflammatory compounds will be identified. This opens new 
perspectives for the use of these drugs in the prevention of adenocarcinoma and 
treatment of Barrett’s esophagus.
  In a segment of columnar epithelium in the esophagus the distribution of intes-
tinal metaplasia is usually patchy. Therefore, regions with intestinal metaplasia 
are often missed, which is called sampling error. Since CDX2 marks the presence 
of hybrid epithelium that is associated with the presence of intestinal metaplasia, 
CDX2 could function as a marker for intestinal differentiation during routine histol-
ogy, to reduce sampling error. 
  Although Barrett’s esophagus can be easily distinguished from normal esopha-
geal mucosa, both on the endoscopical and histological level, the diagnosis of 
Squamous 
epithelium
Barrett’s 
esophagus
High-grade adenocarcinoma
Reflux
Acid, bile 
CDX2 MUC2
MUC5AC
MUC6
Calgranulin A 
Calgranulin B 
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Mip-3
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Mip-3a
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Figure 1   The development of Barrett’s esophagus, dysplasia, and esophageal adenocarcinoma from 
squamous epithelium- and the molecular alterations described in this thesis that occur during this se-
quence. The components of the gastro-esophageal refluxate damage the epithelial cells, that will release 
inflammatory mediators, such as MIP-3α, MEC, and IL-8. These compounds attract inflammatory cells 
that will cause DNA damage in the epithelium. Some mutations will cause growth advantage and these 
cells will grow out to dysplasia, which can eventually progress to esophageal adenocarcinoma.
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dysplasia is more complex. It is difficult to distinguish high-grade dysplasia from 
low-grade dysplasia and non-dysplastic Barrett’s esophagus. Along with other 
findings, MUC4 and calgranulin A and B may function as molecular marker in the 
early detection of high-grade dysplasia and esophageal adenocarcinoma. Fur-
thermore, insights in the processes that regulate the development of high-grade 
dysplasia can provide tools for the prevention of this process.
CONCLUDING REMARKS
The irritation of the esophageal epithelium by gastroesophageal reflux results 
in chronic inflammation and causes the induction of molecular and cellular al-
terations. Figure 1 gives a schematic overview of the molecular events that are 
characterized in this thesis. These events represent only a small proportion of all 
molecular changes that occur, some of them are described and many other have 
not yet been discovered. Despite the small proportion of alterations described in 
this thesis, the results that are described provide new insights in the develop-
ment of Barrett’s esophagus, dysplasia, and adenocarcinoma. Moreover, all these 
results will have clinical implications for the diagnosis, prevention, and treatment 
of these lesions.
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Figure 1   CDX2 protein in Barrett’s esophagus, esophageal adenocarcinoma, and reflux esophagitis. (A) 
A positive nuclear stain (red) for CDX2 was observed in 16/16 samples of Barrett’s esophagus. A repre-
sentative slide of patient 10 is shown. (B) The presence of CDX2 was associated with goblet cells, which 
are characteristic of Barrett’s esophagus, as was shown in an Alcian Blue at pH 2.5 stain of a serially 
sectioned slide of the same patient. (C) CDX2 was also present in 4/4 adenocarcinomas, which can be 
seen in a slide of patient 3. (D) CDX2 was absent in the squamous epithelium of all patients with reflux 
esophagitis (0/20).
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Figure 1   Histological and immunohistochemical detection of intestinal characteristics. A Nuclear CDX2 
expression in gastric-type glands at a distance of IM (arrow)(200x magnification). B The same region. 
Alcian Blue staining in adjacent gastric-type glands does not detect goblet cells (200x magnification). C 
cytoplasmic MUC2 staining in goblet cells (400x magnification). D Haematoxylin and Eosin staining in the 
same region (400x magnification). E Diffuse cytokeratin 7 staining in IM (100x magnification). F Super-
ficial cytokeratin 20 staining in the same region (100 x magnification).
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Figure 1   Immunohistochemical and histological analyses of CDX2 staining. a-b CDX2 and alcian blue 
staining in IM, 200 x magnification. c-d CDX2 and alcian blue staining of GM in samples without IM, 200 
x magnification. e-f CDX2 and alcian blue staining in gastric-type glands adjacent to IM, the region with 
IM is not visible in this picture, but located on the left sight of this picture. 200 x magnification. g-h CDX2 
and alcian blue staining in gastric-type glands at distance of IM, the region with IM is not visible in this 
picture, but is located on the other (left) site of this picture. 200 x magnification.
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Figure 2   Immunohistochemical and histological analyses of MUC2 staining. a-b MUC2 and alcian blue 
staining of GM in samples without IM. The same region as Figure 1c-d is shown. 200x magnification. c-d 
Magnified view of MUC2-staining goblet-like cells in gastric-type glands.1000x magnification.
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Figure 2   Haematoxylin and eosin stained control sections for high-grade dysplasia (HGD) (A) and non-
dysplastic Barrett’s oesophagus (BE) (B). In HGD, calgranulin A is present in the entire cytoplasm (C, 
arrow), while in BE it was only observed on the basal site of the cell (D, arrow). Staining patterns for 
calgranulin B in HGD (E) and BE (F) resemble those of calgranulin A, except for an intense background 
staining probably due to aspecific staining of the polyclonal antibody. FABP1 is present in a small subset 
of cells in HGD (G, arrow), while it was observed in the entire top of the villus in BE (H).
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Barrett-slokdarm is een afwijking die veel voorkomt, vooral in de westerse wereld. 
Waarschijnlijk heeft 1-5% van de inwoners van Noord-Amerika en Europa deze 
afwijking. Hoewel de meeste patiënten met een Barrett-slokdarm geen klachten 
hierdoor hebben, geeft de aanwezigheid van een Barrett-slokdarm toch een dertig 
keer grotere kans op het ontstaan van één van de vormen van slokdarmkanker, 
namelijk het adenocarcinoom. De ontwikkeling van een adenocarcinoom in de 
slokdarm gaat meestal geleidelijk, via de tussenstadia laaggradige en hooggra-
dige dysplasie. Om de aanwezigheid van een adenocarcinoom in een vroeg sta-
dium op te kunnen sporen, worden patiënten eens in de twee jaar endoscopisch 
onderzocht.
  Barrett-slokdarm wordt waarschijnlijk veroorzaakt door het oprispen van maag-
zuur en gal uit de twaalfvingerige darm. Dit oprispen wordt reflux genoemd. Het 
maagzuur en de galzuren zijn schadelijk voor het normale slijmvlies van de slok-
darm, dat door de blootstelling hieraan geïrriteerd raakt. Door deze irritatie zal 
in ongeveer tien procent van de mensen die last hebben van reflux, het normale 
slijmvlies van de slokdarm vervangen worden door slijmvlies dat lijkt op dat van 
de darmen, Barrett-slijmvlies. Het Barrett-slijmvlies is beter bestand tegen het 
schadelijke effect van maagzuur en galzuren, maar het is er niet helemaal onge-
voelig voor. De blootstelling aan het maagzuur en de galzuren kan het slijmvlies 
aanzetten tot het produceren van eiwitten die ontstekingscellen aantrekken. Deze 
eiwitten worden chemokines en cytokines genoemd. Het voortdurend oprispen 
van zuur en gal leidt uiteindelijk tot de permanente aanwezigheid van ontste-
kingscellen, waardoor er een chronische ontsteking van het slijmvlies ontstaat.
  Eén van de normale functies van de ontstekingscellen is het verwijderen van 
slijmvliescellen die ernstig beschadigd zijn. Om deze beschadigde cellen te doden, 
worden radicalen uitgescheiden. Radicalen zijn reactieve moleculen die DNA kun-
nen beschadigen. Cellen met DNA schade gaan normaalgesproken dood, maar 
sommige cellen zullen de DNA schade overleven. Door DNA schade kan kanker 
ontstaan. Wanneer de DNA schade optreedt in een gen dat tumorgroei afremt, 
en als het eiwit waarvoor het gen codeert door deze schade niet goed meer func-
tioneert kan een cel ongeremd gaan delen waardoor de tumor groeit. Datzelfde 
geldt als er schade optreedt die ervoor zorgt dat een niet actief gen dat betrokken 
is bij celdeling, aangezet wordt. Omdat deze cellen hogere delingssnelheid heb-
ben dan normale cellen, kunnen ze uitgroeien tot een tumor. Een uitgebreidere 
beschrijving van deze theorie en de literatuur die eraan ten grondslag ligt, wordt 
beschreven in hoofdstuk 2. 
HET ONTSTAAN VAN BARRETT-SLOKDARM
Barrett-slijmvlies lijkt op het slijmvlies van de darmen, zowel microscopisch als 
moleculair-biologisch. Net als in darmslijmvlies zijn in Barrett-slijmvlies slijmbe-
kercellen, grote, slijmproducerende cellen, aanwezig. CDX2 is een eiwit dat be-
trokken is bij het ontstaan van darmslijmvlies. Het is een transcriptiefactor, een 
eiwit dat andere genen “aanzet”. CDX2 zet genen aan die specifieke darmfuncties 
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hebben, zoals darmenzymen en eiwitten die de slijmlaag op het darmslijmvlies 
vormen. Omdat Barrett-slijmvlies op darmslijmvlies lijkt, hebben we de hypothese 
geformuleerd dat CDX2 ook aanwezig is in Barrett-slijmvlies. Deze hypothese 
werd getest en bevestigd in hoofdstuk 3. CDX2 werd niet alleen gevonden in 
het Barrett-slijmvlies, maar ook in het naastliggende normale slijmvlies van de 
slokdarm, alhoewel in kleine hoeveelheden. Dit kan betekenen dat CDX2 een be-
paald soort weefsel dat al wel bepaalde intestinale eiwitten produceert, maar dat 
nog niet echt een intestinaal fenotype heeft, kan aantonen. Deze theorie werd 
verder onderzocht in hoofdstuk 4 en hoofdstuk 5. In deze hoofdstukken werd 
gekeken naar de expressie van CDX2 in maag-type slijmvlies in de slokdarm. Dit 
type slijmvlies lijkt op Barrett-slijmvlies, maar er zijn geen slijmbekercellen in 
aanwezig. Daarom worden de twee slijmvliessoorten als aparte soorten gezien, 
zeker ook omdat de aanwezigheid van maag-type slijmvlies geen groter risico op 
het ontwikkelen van slokdarmkanker vormt. In hoofdstuk 4 en 5 werd gevonden 
dat CDX2 expressie ook in sommige gebieden met maag-type slijmvlies in de 
slokdarm aanwezig is. In deze gebieden werd ook expressie van een ander dar-
meiwit, MUC2, gevonden. Dit betekent dat het maagtype slijmvlies waarin CDX2 
en MUC2 voorkomen een soort kruising is tussen normaal maag-type slijmvlies in 
de slokdarm en Barrett-slijmvlies. Maag-type slijmvlies en Barrett-slijmvlies zijn 
dus waarschijnlijk verwant aan elkaar.
  Het darmeiwit MUC2 behoort tot de familie van de mucines. Er zijn twee groe-
pen mucines. Eén groep wordt uitgescheiden door het slijmvlies en vormt een 
beschermende, slijmlaag die het slijmvlies beschermt tegen mechanische schade 
door voedselbrokken die door het maag-darmkanaal passeren, en tegen chemi-
sche schade door stoffen zoals gal en verteringsenzymen. De andere groep blijft 
aan het celoppervlak gebonden en vormt zo op de cel een beschermende laag. 
Elk type slijmvlies heeft een specifiek patroon van de mucines die geproduceerd 
worden. In hoofdstuk 6 wordt het mucine-patroon van Barrett-slijmvlies en nor-
maal slokdarmslijmvlies beschreven. In Barrett-slijmvlies worden voornamelijk 
mucines die door het slijmvlies uitgescheiden worden geproduceerd, terwijl in 
normaal slokdarmslijmvlies juist mucines die gebonden zijn aan het membraan 
aanwezig zijn. Het veranderde mucinepatroon in Barrett-slijmvlies is waarschijn-
lijk het gevolg van het aanpassen van het slijmvlies aan de irriterende werking 
van het opgerispte zuur en gal.
  Omdat gal een van de belangrijkste componenten van het oprispte refluxaat is, 
werd in hoofdstuk 8 het effect van galzuren op Barrett-slijmvlies en normale 
slijmvlies van de slokdarm onderzocht. Hiervoor werd een model voor deze twee 
slijmvlies-types gebruikt, waarbij gekweekte kankercellen werden blootgesteld 
aan het galzuur deoxycholzuur, een van de belangrijke componenten van de opge-
rispte gal. Het blootstellen van de gekweekte cellen aan deoxycholzuur leidde tot 
een toename van de expressie van een aantal chemokines. Chemokines zijn eiwit-
ten die meestal door slijmvliescellen worden uitgescheiden om ontstekingscellen 
aan te trekken. De chemokines die in dit model toenamen, trekken specifieke 
ontstekingscellen aan, waarvan is aangetoond dat ze aanwezig zijn in een Barrett-
slokdarm. Dit betekent dat in een Barrett-slokdarm de irritatie, veroorzaakt door 
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het oprispen van gal, kan leiden tot een toename van het aantal ontstekingscel-
len, die voor verdere schade aan het slijmvlies kunnen zorgen.
HET ONTSTAAN VAN DYSPLASIE EN KANKER IN EEN BARRETT-SLOKDARM
Barrett-slijmvlies is metaplastisch, wat betekent dat het bestaat uit cellen die zijn 
gevormd op een plek waar ze niet thuishoren. Omdat deze cellen door de irritatie 
door zuur en gal waarschijnlijk beschadigd raken, moeten ze regelmatig vervangen 
worden. Deze twee dingen betekenen dat Barrett-slijmvliescellen sneller kunnen 
delen dan normale slijmvliescellen en een toegenomen celdelingssnelheid is een 
risicofactor voor het ontstaan van kanker. Verder kunnen de ontstekingscellen die 
zorgen voor de chronische ontsteking die aanwezig is in Barrett-slijmvlies verdere 
schade aan het slijmvlies veroorzaken, doordat ze radicalen produceren die het 
DNA van de slijmvliescellen kunnen beschadigen. Ook DNA schade, zoals mutaties 
in genen die de delingssnelheid van cellen reguleren, is een risicofactor voor het 
omvormen van een normale cel naar een kankercel. De aanwezigheid van deze 
risicofactoren in Barrett-slijmvlies betekent dat de slijmvliescellen kunnen veran-
deren in sneller delende, mutatie-bevattende cellen. Dit slijmvlies is echter nog 
niet compleet ontspoord en wordt daarom gezien als een voorstadium van kanker, 
dysplasie genoemd. In een Barrett-slokdarm wordt onderscheid gemaakt tussen 
laaggradige en hooggradige dysplasie. Wanneer hooggradige dysplasie aanwezig 
is, is de kans dat er kanker zal ontstaan erg groot. 
  Het mucinepatroon verandert vaak gedurende de ontwikkeling van kanker. Het 
mucinepatroon in hooggradige dysplasie in Barrett-slijmvlies is beschreven in 
hoofdstuk 6. Hier wordt beschreven dat de expressie van MUC4, een mucine dat 
is gebonden aan het celmembraan, is verhoogd in hooggradige dysplasie en in een 
adenocarcinoom in de slokdarm. MUC4 is waarschijnlijk direkt betrokken bij het 
kankerproces. Kankercellen hebben op het celoppervlak vaak tekens die herkend 
worden door het immuunsysteem, waardoor de kankercellen gedood kunnen wor-
den. MUC4 heeft net als alle andere mucines veel suikerketens op het oppervlak, 
en deze kunnen de kankerceltekens verbergen, waardoor het immuunsysteem 
de cellen niet herkent als kankercellen, en waardoor de cellen niet opgeruimd 
worden. Verder is ook beschreven dat MUC4 is betrokken bij het remmen van ge-
programmeerde celdood (apoptose), een proces dat ervoor zorgt dat beschadigde 
cellen doodgaan, waardoor ze plaats kunnen maken voor niet-beschadigde cellen. 
Verminderde apoptose is één van de kenmerken van kanker. Wij vonden echter 
juist een toename in apoptose in hooggradige dysplasie. Toegenomen apoptose 
is beslist geen kenmerk van kanker ontwikkeling, echter hooggradige dysplasie 
is nog niet compleet ontspoord en door meer apoptose zou het slijmvlies kunnen 
compenseren voor andere kanker-inducerende veranderingen. In adenocarcino-
men van de slokdarm, die veel verder ontspoord zijn, werd wel een sterke afname 
in apoptose gemeten. 
  In hoofdstuk 7 worden twee andere eiwitten beschreven die verhoogd tot ex-
pressie komen in hooggradige dysplasie. Deze eiwitten, calgranulin A en B vormen 
A
pp
en
di
x
122
Nederlandse samenvatting 123
samen het calprotectine complex, dat net als chemokines ontstekingscellen aan-
trekt, in dit geval neutrofiele granulocyten. Neutrofiele granulocyten produceren 
veel radicalen die DNA schade kunnen veroorzaken, waardoor de slijmvliescellen 
verder kunnen ontsporen. Daarnaast wordt calprotectine ook geproduceerd in het 
normale slijmvlies van de slokdarm, waar het waarschijnlijk betrokken is bij de 
celdeling. 
  De aanwezigheid van tumorgroei-stimulerende mutaties in hooggradige dyspla-
sie kan leiden tot meer mutaties, bijvoorbeeld wanneer er een mutatie optreedt 
in een gen dat zorgt voor het opsporen en repareren van DNA schade. Deze 
mutaties kunnen leiden tot de ontwikkeling van een adenocarcinoom in de slok-
darm. Chemokines kunnen bijdragen aan tumorgroei door ontstekingscellen aan 
te zetten tot het produceren van stoffen die de structuren buiten de cel afbreken. 
Deze structuren zorgen ervoor dat de cellen op hun plaats blijven. Wanneer deze 
afgebroken worden, kunnen tumorcellen makkelijk ingroeien in andere organen, 
of uitzaaien via de lymfe- of bloedvaten. In hoofdstuk 8 werd de chemokine 
expressie in Barrett-slokdarm monsters vergeleken met een aantal dysplasie en 
adenocarcinoom monsters. Er werd gevonden dat de expressie van een aantal 
chemokines verhoogd was in de adenocarcinoom monsters. Dit kan betekenen dat 
deze chemokines, naast hun rol in het aantrekken van ontstekingscellen, ook een 
rol spelen bij het ontstaan van slokdarmkanker.       
KLINISCHE BETEKENIS VAN DIT PROEFSCHRIFT
Het is belangrijk dat de rol van ontsteking en de moleculaire veranderingen die 
optreden tijdens de ontwikkeling van een Barret-slokdarm beter begrepen wordt, 
want hierdoor kunnen er nieuwe aangrijpingspunten gevonden worden voor mo-
gelijke nieuwe geneesmiddelen. Deze kunnen gebruikt worden om Barrett-slok-
darm te voorkomen en te behandelen. 
  Er zijn veel middelen, zoals NSAID’s (niet-steroide anti-inflammatoire middelen) 
op de markt die ontsteking kunnen remmen. Ook worden er op het gebied van 
ontstekingsremmers nog steeds veel nieuwe middelen ontwikkeld. Het beschrij-
ven van de cytokines en chemokines die een rol spelen bij de ontwikkeling van 
een Barrett-slokdarm, zoals in dit proefschrift in hoofdstuk 8 is gebeurd met een 
aantal chemokines, is belangrijk, omdat juist deze stoffen een belangrijk doel zijn 
voor ontstekingsremmers. Zo zou kunnen blijken dat ontstekingsremmers die tot 
nu toe werden gebruikt bij andere aandoeningen, ook helpen bij het verminderen 
van de ontsteking in een Barrett-slokdarm. Behandeling met deze ontstekings-
remmers zou mogelijk ook kunnen leiden tot een verminderde kans op het ont-
staan van een adenocarcinoom. 
  Verder kunnen ook de moleculaire veranderingen die optreden tijdens de ont-
wikkeling van dysplasie en kanker in een Barrett-slokdarm gebruikt worden om 
een betere diagnose te stellen. Het eiwit CDX2 zou mogelijk gebruikt kunnen 
worden om een nauwkeurigere diagnose van een Barrett-slokdarm te krijgen. In 
een gebied wat endoscopisch gezien allemaal Barrett-slijmvlies lijkt te zijn, blijkt 
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na microscopisch onderzoek het echte Barrett-slijmvlies vaak in de minderheid te 
zijn, omdat er ook veel maagslijmvlies aanwezig is. Wanneer er in de biopten al-
leen maar maag-slijmvlies aanwezig is komt de patiënt niet in aanmerking voor de 
tweejaarlijkse controle op dysplasie en kankerontwikkeling. De diagnose van Bar-
rett-slijmvlies wordt gesteld op een aantal biopten die uit een willekeurig gedeelte 
van de slokdarm worden genomen, kan het zijn dat kleine regio’s met echt Bar-
rett-slijmvlies worden gemist tijdens het biopteren. Wanneer er CDX2 aanwezig 
blijkt te zijn in het maag-slijmvlies, is dat een goede aanwijzing dat er elders echt 
Barrett-slijmvlies aanwezig is. 
  Het verschil tussen Barrett-slijmvlies en het normale slijmvlies van de slokdarm 
is endoscopisch heel goed te zien, maar het zien van dysplasie is veel lastiger. Ook 
microscopisch is het lastig om dysplasie te onderscheiden van normaal Barrett-
slijmvlies. Het gebruik van een aantal “markers”, eiwitten in een bepaald stadium 
aanwezig zijn en in een ander stadium niet, zou de diagnose kunnen vergemak-
kelijken. Samen met eiwitten die al eerder in de literatuur zijn beschreven zouden 
MUC4 en Calgranulin A en B kunnen helpen bij het vroege opsporen van hoog-
gradige dysplasie. 
Normaal slokdarm 
slijmvlies 
Barrett-slokdarm Hooggradige adenocarcinoom
Reflux
Zuur, gal 
CDX2 MUC2
MUC5AC
MUC6
calgranulin A 
calgranulin B 
MUC4
MIP-3
MEC
Ontsteking
MIP-3
MEC
IL-8
schade
dysplasie
Figuur 1   De ontwikkeling van een Barrett-slokdarm, dysplasie en een adenocarcinoom vanuit normaal 
slokdarmslijmvlies en de moleculaire veranderingen die beschreven zijn in dit proefschrift, die optreden 
tijdens dit proces. Gal en zuur, de componenten van reflux, beschadigen de slijmvliescellen waardoor 
deze ontstekingsfactoren zoals MIP-3α, MEC en IL-8. Deze stoffen trekken ontstekingscellen aan en die 
kunnen zorgen voor DNA schade. Wanneer deze schade optreedt in bepaalde genen, kunnen de cellen 
harder gaan groeien. Hierdoor groeien ze uit tot dysplasie, die uiteindelijk kan overgaan in een adeno-
carcinoom.
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CONCLUSIE
Het oprispen van zuur en gal kan irritatie van het slokdarmslijmvlies veroorzaken. 
Door deze irritatie raakt het slijmvlies chronisch ontstoken. De ontsteking kan lei-
den tot allerlei moleculaire veranderingen in de cel. De moleculaire veranderingen 
die zijn beschreven in dit proefschrift (Figuur 1) vormen slechts een klein gedeelte 
van alle veranderingen die optreden, sommige reeds beschreven, maar andere 
nog niet ontdekt. Ondanks dat het aantal veranderingen dat hier beschreven is, 
niet erg groot is, kunnen de beschreven veranderingen toch leiden tot nieuwe 
inzichten in het ontstaan van een Barrett-slokdarm, dysplasie en slokdarmkanker. 
De resultaten beschreven in dit proefschrift zullen in de toekomst mogelijk leiden 
tot nieuwe mogelijkheden voor de diagnose, preventie en behandeling van deze 
aandoeningen.
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CURRICULUM VITAE
Dorine Bax werd op 16 februari 1979 geboren in Dordrecht en groeide op in 
Hendrik-Ido-Ambacht. Zij behaalde in 1997 het VWO diploma aan het Devel-
steincollege te Zwijndrecht. In datzelfde jaar startte ze met de studie Medische 
Biologie aan de Vrije Universiteit in Amsterdam. Tijdens deze studie deed ze een 
onderzoekstage op de afdeling Medische Microbiologie en Infectiepreventie van 
het VUMC. Onder begeleiding van Monique Gerrits en Hans Kusters werd er on-
derzoek gedaan naar het moleculaire mechanisme van metronidazol-resistentie 
van Helicobacter Pylori. Een tweede onderzoeksstage werd gedaan op de afdeling 
Klinische Viro-Immunologie van het Centraal Laboratorium van de Bloedtrans-
fusiedienst in Amsterdam (CLB/Sanquin). Onder leiding van Tim Beaumont en 
Hanneke Schuitemaker werd er onderzoek gedaan naar de neutralisatiegevoelig-
heid van het HIV-1 virus. In 2001 behaalde ze het doctoraal examen. Aansluitend 
startte ze haar promotieonderzoek op de afdeling Maag-, Darm- en Leverziekten 
van het Erasmus MC in Rotterdam naar moleculaire veranderingen die optreden 
gedurende de ontwikkeling van een Barrett-slokdarm en een slokdarm adenocar-
cinoom. Onder begeleiding van Hans Kusters, Peter Siersema en Ernst Kuipers 
werd het onderzoek verricht dat in dit proefschrift beschreven is. 
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DANKWOORD
Nog niet zo lang geleden werd mij door een collega verteld dat hoe meer mensen 
je bedankt in een dankwoord, hoe meer je er ook vergeet. Toch is het niet mijn 
stijl om me er hier met een kort stukje vanaf te maken. De afgelopen jaren ben ik 
door talloze mensen geholpen om voor elkaar te krijgen dat er nu een proefschrift 
ligt. Natuurlijk was dit onderzoek niet mogelijk geweest zonder de medewerking 
van vele patiënten die materiaal hebben afgestaan en daarvoor wil ik hen graag 
bedanken. 
  Zes jaar geleden kwam ik als verlegen, stille studente voor het eerst binnen-
wandelen bij Hans Kusters, toen nog op de afdeling Medische Microbiologie en 
Infectiepreventie van de Vrije Universiteit in Amsterdam. Hans krabbelde in twin-
tig minuten enthousiast alle onderzoekslijnen van de afdeling op een leeg A4-tje 
en een half uur later stond ik helemaal in de war weer buiten. Toch ben ik mijn 
eerste stage bij hem (en bij Simone en Monique) gaan lopen. Een periode die zes 
maanden had moeten duren, maar het werden er uiteindelijk tien, want ik had het 
geweldig naar mijn zin. Het was ook geen moeilijke beslissing om na mijn afstu-
deren in Rotterdam bij Hans promotieonderzoek te gaan doen. Beste Hans, heel 
veel dank dat ik promotieonderzoek bij je mocht doen. De afgelopen vier jaar heb-
ben we heel fijn samengewerkt. Je bleef me begeleiden met het enthousiasme dat 
je al had tijdens ons eerste gesprek. Zonder jou had dit boekje er niet gelegen!
  Toen ik begon met mijn promotieonderzoek stapte ik voor het eerst de wereld 
van de artsen binnen. Hun veeleisendheid en manier van reageren was nieuw voor 
me. Mijn eerste echte ontmoeting met Peter Siersema was er één om nooit te ver-
geten. Ik moest een aantal biopten opvangen tijdens een endoscopie, en kennelijk 
was ik niet snel genoeg, want ik kreeg een boetpredikatie waarvan ik tien minuten 
later terug op mijn kamer nog stond te trillen op mijn benen. Mijn kamergenoten 
meldden me fijntjes dat zo’n reactie heel normaal was voor Peter. Het heeft dan 
ook nog even geduurd eer dat ik een samenwerking aandurfde. Uiteindelijk zijn 
we samen aan de slag gegaan met het galzuuronderzoek dat hij meebracht vanuit 
Stanford. Ik heb hem toen leren kennen als iemand die helemaal voor het onder-
zoek gaat en die heel veel doet voor “zijn” promovendi. Verdere boetpredikaties 
zijn uitgebleven. Beste Peter, jouw manier van onderzoek doen heeft me ontzet-
tend gestimuleerd om dingen verder uit te zoeken. Ik kijk terug op een ontzettend 
prettige samenwerking. Bedankt!
  De afgelopen vier jaar ging ik ongeveer eens in de drie maanden verslag uitbren-
gen bij professor Kuipers. Het heeft me ontzettend verbaasd hoe hij in staat was 
om zich binnen een kwartiertje op de hoogte te stellen van de vorderingen bij al 
mijn onderzoekslijnen, daarbij nog een paar kritische noten te plaatsen, en ver-
volgens ook nog te informeren hoe mijn vakantie was geweest. Beste Ernst, heel 
erg bedankt voor je ontzettend positieve manier van begeleiden. Na één besprek-
ing met jou zag ik mijn onderzoek altijd weer helemaal zitten!
  Tijdens een promotie zijn er altijd personen die onvoorwaardelijk bereid zijn je te 
helpen. Met één daarvan, of beter gezegd, met zijn potjes met oplossingen die al-
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tijd naar mijn kant van de labtafel werden geschoven, maakte ik al kennis tijdens 
mijn stage. Beste Arnoud, ontzettend veel dank voor al je hulp bij het uitvoeren 
van mijn onderzoek, het schrijven van de artikelen, maar ook bij alle (computer) 
problemen!
  De afgelopen jaartjes heb ik heel wat uurtjes doorgebracht op de endoscop-
iekamer. Ik werd daar wegwijs gemaakt in de endoscopiewereld door Jelle Har-
ingsma. Beste Jelle, bedankt voor het meehelpen met verzamelen van patiënten-
materiaal en voor het meedenken met mijn onderzoek!
  Toen ik net een paar maanden begonnen was, diende zich alweer een nieuwe AIO 
in de Barrett’s groep aan: Leon Moons. Een vat vol ideeën en altijd enthousiast 
over ons onderzoek, wat al snel in onze eerste gezamenlijke publicatie resulteerde. 
Beste Leon, we hebben de afgelopen jaren heel veel en heel fijn samengewerkt. 
Bedankt voor al je hulp!
  Onderzoek op het gebied van de maag-, darm- en leverziekten kan eigenlijk niet 
zonder de hulp van een patholoog. Gelukkig was Herman van Dekken altijd bereid 
om even tijd te maken als er weer een paar coupes bekeken moesten worden. 
Beste Herman: bedankt hiervoor!
  In de vier jaren die ik op de afdeling maag-, darm- en leverziekten heb doorge-
bracht is de Barrett’s groep van een groepje met slechts een paar promovendi 
uitgegroeid tot een enorme groep met meer dan tien promovendi. Beste Rudy, 
Marjolein, Mariska, Els, Marjon, Eva, Evelien, Marieke, Vivianda, Pieter-Jan, en 
Madeleen bedankt voor onze samenwerking!
  Ook het MDL-lab is twee keer zo groot geworden in de periode dat ik er werkte. 
Omdat er onderzoek wordt gedaan in heel veel disciplines, kun je altijd dichtbij te 
rade gaan als je iets nieuws wilt gaan proberen. Beste Jaap, Luc, Renate, Hanneke 
en Monique bedankt voor alle adviezen!
  Toen er aan het eind van mijn onderzoek opeens nog wel heel erg veel op het lab 
gedaan moest worden, kwam er gelukkig hulp. Beste Mieke en Anthonie, bedankt 
voor alle experimenten die jullie voor mij gedaan hebben!
  In de vier jaar waarin ik dit promotieonderzoek heb gedaan, hebben er ook drie 
studenten meegewerkt. De rol als begeleider was niet altijd even makkelijk, maar 
uiteindelijk hebben ze flink geholpen door elk een stukje van het onderzoek uit te 
voeren. Beste Isis, Arthur en Faziel bedankt!
  Tijdens het uitvoeren van mijn onderzoek waren er ontelbare dingen die gedaan 
moesten worden, maar waar ik geen tijd voor had. Beste Linda, heel veel dank 
voor alle hulp die ik van jou heb gekregen! Beste Wendy en Carla, heel veel dank 
voor het regelen van afspraken en het zorgen voor allerlei papierwerk! Beste 
Greta, al jouw hulp met het vullen van puntjes, afwassen e.d. heeft me echt heel 
veel tijd bespaard. Bedankt daarvoor!
  Door de jaren heen was er één heel speciale groep met collega’s met wie ik veel 
lief en leed heb gedeeld: mijn kamergenoten. Ik heb met veel mensen de kamer 
gedeeld en altijd was het net iets te gezellig! Beste Rudy, Thjon, Dave, Florian, 
Brenda, Thanya, Jan, Martine, Angela en Astrid ontzettend bedankt voor alle ge-
sprekken, de gezelligheid en jullie luisterend oor!
  Er zijn nog heel veel collega’s die ik niet bij naam bedankt heb, en als ik dat wel 
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ga doen dan wordt dit stuk echt te lang vrees ik. Daarom bij deze: beste collega’s 
van het MDL-lab ontzettend bedankt voor de fantastische tijd die ik heb gehad met 
jullie. Ook al ging niet alles over rozen, het zal toch een periode zijn waar ik altijd 
met veel plezier op terug blijf kijken!
   Promotieonderzoek is niet vol te houden als je niet af en toe je zinnen kunt 
verzetten naar iets heel anders. Gelukkig had ik mijn vrienden om regelmatig 
leuke dingen mee te doen, maar die ook altijd voor me klaarstonden als er iets 
even iets minder ging. Beste Jeroen, Annemarie, Erwin, Bianco, Marieke, Hessel, 
Paulien en alle andere vrienden, bedankt voor alles!
  Als laatste, maar zeker niet als minste, wil ik mijn familie bedanken. Lieve Papa 
en Mama, jullie zijn me altijd door dik en dun blijven steunen. Het is heel fijn om 
te weten dat jullie trots op ons zijn! Ik houd veel van jullie en dat blijft altijd zo, 
ook op afstand! Lieve Judit, je hebt me geweldig geholpen met de layout. Zonder 
jou had dit boekje er niet zo uitgezien! Heel erg bedankt voor alle hulp! Lieve Ren-
ske, je wilde altijd even weten hoe alles ging en had altijd belangstelling voor wat 
ik deed. Ik ben heel blij dat Judit en jij mijn paranimfen willen zijn! Lieve papa, 
mama, Judit, Bart-Jan, Renske en Gijs, bedankt dat jullie er altijd waren om op 
terug te vallen!
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